x ☒QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

(Former name, former address and former three months, if changed since last report)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x ☒ No ¨☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x ☒ No ¨☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ ☐ No x☒

As of May ~~15, 2020,~~17, 2021, there were ~~13,225,387~~16,066,947 shares issued and ~~12,860,059~~15,716,619 shares outstanding of the registrant’s common stock.

COSMOS HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

		March 31, 2020			December 31, 2019			March 31, 2021			December 31, 2020
		(Unaudited)						(Unaudited)
ASSETS	ASSETS

CURRENT ASSETS:
Cash and cash equivalents		$	984,881		$	38,537		$	431,807		$	628,395
Accounts receivable, net			11,017,329			7,348,945			21,845,148			23,440,650
Accounts receivable - related party			738,283			1,919,043			3,247,612			3,468,564
Marketable securities			212,900			238,940			214,349			222,792
Inventory			3,414,734			3,474,220			3,417,074			3,292,557
Other investments			4,298			4,381
Prepaid expenses and other current assets			1,531,657			1,549,055			4,872,709			5,148,441
Prepaid expenses and other current assets - related party			2,343,924			5,940,124			3,522,041			3,468,653
Operating lease right-of-use asset			441,441			498,180			798,623			833,763
Financing lease right-of-use asset			132,494			167,310			247,463			269,131

TOTAL CURRENT ASSETS			20,821,941			21,178,735			38,596,826			40,772,946

Property and equipment, net			1,705,033			1,734,781			1,623,962			1,757,213
Goodwill and intangible assets, net			255,433			263,681			222,348			230,506
Other assets			689,756			702,439			752,423			905,318
Deferred tax assets									499,368			178,430

TOTAL ASSETS		$	23,472,163		$	23,879,636		$	41,694,927		$	43,844,413

LIABILITIES AND STOCKHOLDERS' DEFICIT
LIABILITIES AND STOCKHOLDERS’ DEFICIT

CURRENT LIABILITIES:
Accounts payable and accrued expenses		$	6,833,489		$	8,561,681		$	11,305,219		$	11,973,981
Accounts payable and accrued expenses - related party			35,162			240,302			27,453			1,733
Accrued interest									1,180,523			742,374
Customer advances			170,990			247,318			22,761			22,340
Convertible notes payable, net of unamortized discount of $0 and $29,509, respectively			1,400,000			1,470,491
Convertible notes payable, net of unamortized discount of $507,483 and $494,973, respectively									859,517			952,027
Derivative liability - convertible note									461,974			460,728
Notes payable			13,297,462			12,029,724			9,233,095			12,042,712
Notes payable - related party			1,346,376			1,375,532			481,698			501,675
Lines of credit			3,435,005			2,750,992			4,780,126			5,076,684
Loans payable - related party			1,487,807			1,026,264			1,941,773			1,629,246
Taxes payable			172,632			175,939			757,635			760,446
Operating lease liability, current portion			111,806			139,556			199,343			200,204
Financing lease liability, current portion			50,064			58,185			68,353			89,926
Other current liabilities			154,668			165,271			459,748			339,000

TOTAL CURRENT LIABILITIES			28,495,461			28,241,255			31,779,218			34,793,076

Share settled debt obligation			1,554,590			1,554,590			1,554,590			1,554,590
Notes payable - long term portion									10,303,924			10,771,882
Operating lease liability, net of current portion			328,309			353,024			570,429			590,538
Financing lease liability, net of current portion			74,681			82,523			188,545			188,172
Other liabilities			107,023			109,073			102,901			107,168
TOTAL LIABILITIES			30,560,064			30,340,465			44,499,607			48,005,426

Commitments and Contingencies (see Note 13)			-			-			-			-

STOCKHOLDERS' DEFICIT:
Preferred stock, $0.001 par value; 100,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively			-			-
Common stock, $0.001 par value; 300,000,000 shares authorized; 13,225,387 shares issued and 12,860,059 outstanding as of March 31, 2020 and December 31, 2019			13,225			13,225
STOCKHOLDERS’ DEFICIT:
Preferred stock, $0.001 par value; 100,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively									-			-
Common stock, $0.001 par value; 300,000,000 shares authorized; 16,066,947 and 13,485,128 shares issued and 15,716,619 and 13,069,800 outstanding as of March 31, 2021 and December 31, 2020, respectively									16,066			13,484
Additional paid-in capital			13,525,749			13,525,749			18,333,867			14,333,285
Treasury stock, 365,328 shares as of March 31, 2020 and December 31, 2019			(411,854	)		(411,854	)
Treasury stock, 350,328 and 415,328 shares as of March 31, 2021 and December 31, 2020, respectively									(611,204	)		(611,854	)
Accumulated deficit			(20,054,920	)		(19,571,610	)		(20,924,727	)		(18,750,824	)
Accumulated other comprehensive loss			(160,101	)		(16,339	)
Accumulated other comprehensive gain									381,318			854,896

TOTAL STOCKHOLDERS' DEFICIT			(7,087,901	)		(6,460,829	)
TOTAL STOCKHOLDERS’ DEFICIT									(2,804,680	)		(4,161,013	)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT		$	23,472,163		$	23,879,636

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT								$	41,694,927		$	43,844,413

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

The accompanying notes are an integral part of these unaudited consensed consolidated financial statements.

COSMOS HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

	Three Months Ended March 31,						Three Months Ended March 31,
	2020			2019			2021			2020

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(483,310	)	$	(217,173	)	$	(2,173,903	)	$	(483,310	)
Adjustments to Reconcile Net Loss to Net Cash Used In Operating Activities:
Depreciation and amortization expense		61,760			56,373			80,318			61,760
Amortization of right-of-use assets		38,248			69,632			26,755			38,248
Amortization of debt discounts		29,509			229,713			50,109			29,509
Lease expense		53,600			-			64,543			53,600
Interest on finance leases		2,301			-			4,453			2,301
(Gain) loss on change in fair value of equity investments		22,172			(606,125	)
Stock based compensation								1,189,450			-
Deffered income taxes								(329,586	)		-
Gain on extinguishment of debt								(445,636	)		-
Change in fair value of the derivative liability								(61,373	)		-
Loss on change in fair value of equity investments								440			22,172
Changes in Assets and Liabilities:
Accounts receivable, net		(3,668,384	)		(816,540	)		729,802			(3,668,384	)
Accounts receivable - related party		1,180,760			(269,447	)		197,334			1,180,760
Inventory		59,486			452,208			(246,664	)		59,486
Prepaid expenses and other current assets		17,398			290,663			(1,088,881	)		17,398
Prepaid expenses and other current assets - related party		3,596,200			(31,767	)		(196,436	)		3,596,200
Other assets		12,683			8,551			157,915			12,683
Accounts payable and accrued expenses		(1,728,192	)		349,271			847,525			(1,917,115	)
Accounts payable and accrued expenses - related party		(205,140	)		(10,884	)		25,996			(205,140	)
Accrued interest								438,149			188,923
Customer advances		(76,328	)		50,866			1,333			(76,328	)
Other current liabilities		(10,603	)		(41,426	)		120,748			(10,603	)
Lease liabilities		(41,542	)		(27,417	)		(36,772	)		(41,542	)
Taxes payable		(3,307	)		-			-			(3,307	)
Other liabilities		(2,050	)		29,569			(20,958	)		(2,050	)
NET CASH USED IN OPERATING ACTIVITIES		(1,144,739	)		(483,933	)		(665,339	)		(1,144,739	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets		(54,223	)		(462,545	)		(2,310	)		(54,223	)
Proceeds from sale of investments		-			333,014
NET CASH USED IN INVESTING ACTIVITIES		(54,223	)		(129,531	)
								(2,310	)		(54,223	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of convertible note payable		(100,000	)		(365,513	)		(180,000	)		(100,000	)
Proceeds from convertible note payable		-			-			100,000			-
Payment of related party note payable		(3,305	)		(14,035	)		-			(3,305	)
Proceeds from note payable		1,310,000			-			-			1,310,000
Payment of related party loan		(49,572	)		(38,175	)		(65,761	)		(49,572	)
Proceeds from related party loan		516,819			-			398,457			516,819
Payment of lines of credit		(3,344,072	)		(1,875,720	)		(6,219,899	)		(3,344,072	)
Proceeds from lines of credit		4,079,719			2,518,913			6,123,067			4,079,719
Payments of finance lease liability		(19,886	)		(8,121	)		(25,746	)		(19,886	)
Purchase of treasury stock		-			(71,541	)
Proceeds from sale of treasury stock								250,000			-
NET CASH PROVIDED BY FINANCING ACTIVITIES		2,389,703			145,808			380,118			2,389,703

Effect of exchange rate changes on cash		(244,397	)		(87,031	)		90,943			(244,397	)

NET CHANGE IN CASH		946,344			(554,687	)		(196,588	)		946,344

CASH AT BEGINNING OF PERIOD		38,537			864,343			628,395			38,537
CASH AT END OF PERIOD	$	984,881		$	309,656		$	431,807		$	984,881

Supplemental Disclosure of Cash Flow Information

Cash paid during the period:
Interest	$	124,178		$	119,770		$	208,565		$	124,178
Income tax	$	11,605		$	-		$	-		$	11,605

Supplemental Disclosure of Non-Cash Investing and Financing Activities
Cancellation of pre-delivery shares issued for conversion of convertible notes payable	$	-		$	574

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Conversion of notes payable to common stock							$	2,564,364		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

The terms “COSM,” “we,” “the Company,” and “us” as used in this report refer to Cosmos Holdings, Inc. The accompanying unaudited condensed consolidated balance sheet as of March 31, ~~2020~~2021 and unaudited condensed consolidated statements of operations for the three months ended March 31, ~~2020~~2021 have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management of COSM, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, ~~2020,~~2021, are not necessarily indicative of the results that may be expected for the year ending December 31, ~~2020,~~2021, or any other period. These unaudited consolidated financial statements and notes should be read in conjunction with the financial statements for each of the two years ended December 31, ~~2019~~2020 and ~~2018,~~2019, included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2019~~2020 (“Form 10-K”). The accompanying consolidated balance sheet as of December 31, ~~2019~~2020 has been derived from the audited financial statements filed in our Form 10-K and is included for comparison purposes in the accompanying balance sheet.

Cosmos Holdings Inc. (“us”, “we”, or the “Company”) is ~~an international~~a multinational pharmaceutical ~~wholesaler.~~company. The Company imports, exports and distributes pharmaceutical products of brand-name and generic pharmaceuticals, over-the-counter ~~(“OTC”)~~(OTC) medicines, and a variety of ~~vitamins,~~dietary and ~~dietary supplements. Through March 31, 2020, we operated our~~vitamin supplements through its established network. Currently, the Company operates its business through its three ~~wholly owned~~wholly-owned subsidiaries: (i) SkyPharm, ~~S.A. (“SkyPharm”),~~ headquartered in Thessaloniki, Greece; (ii) Decahedron Ltd. ~~(“Decahedron”)~~, ~~headquartered~~head-quartered in Harlow, United ~~Kingdom (“UK”);~~Kingdom; and (iii) Cosmofarm, ~~Ltd. (“Cosmofarm”),~~ headquartered in Athens, Greece. ~~Our~~Cosmofarm was acquired in 2018 and we believe this expansion has increased our sales and profit margins as we vertically integrate our business ~~is primarily comprised of cross-border sales of brand-name pharmaceutical products in~~model. The Company also has an extensive and established distribution direct and indirect network within the European Union ~~(“EU”)~~(EU). ~~Our~~

The Company’s cross-border pharmaceutical ~~wholesale~~ business serves wholesale pharmaceutical distributors and independent retail pharmacies across the EU through a network of three strategic distribution centers, as well as an additional warehousing facility. Pharmaceutical manufacturers generally implement variable pricing strategies within the EU market. Identifying and evaluating price spreads between EU member states enables usthe Company to source brand-name pharmaceuticals from countries where ex-factory prices are comparatively low and export to countries where the same products are priced higher. ~~We remain focused~~The Company focuses on leveraging ~~our~~its growing purchasing scale and supplier relationships to secure discounts and provide pharmaceuticals at reduced prices and on continuing to drive organic growth at attractive margins for ~~our~~its cross-border pharmaceutical wholesale business.

WeThe Company regularly ~~evaluate~~evaluates and ~~undertake~~undertakes strategic initiatives to expand ~~our~~its distribution reach, improve ~~our~~its profit margins, and strengthen ~~our~~its competitive position. In 2018, wethe Company entered the vitamins and dietary supplements segment and in the fourth quarter of 2018, wethe Company posted the first sales of ~~our~~its own brand of ~~nutraceuticals;~~ ~~SkyPremium Life~~.nutraceuticals: Sky Premium Life. Through the December 2018 acquisition of Cosmofarm, wethe Company entered the full-line pharmaceutical wholesale distribution segment. Cosmofarm now serves approximately ~~370~~1500 independent retail pharmacies and 1540 pharmaceutical wholesalers in the greater Athens, Greece region by providing ~~a reliable supply of~~ brand-name and generic pharmaceuticals, ~~OTC~~over-the-counter medicines, vitamins, and dietary supplements. We invest in technology to enhance safety, distribution and warehousing efficiency and reliability. ~~For example,~~ Cosmofarm operates two ~~fully automated~~robotic ROWA, a German ~~robotic~~fully automated warehouse system, that ensure 0% error selection rate, accelerate order fulfillment, and yield higher cost-efficiency in ~~our~~ Athens distribution center.

We make use of analytics and customer feedback from our EU-wide network of wholesale pharmaceutical distributors and independent retail pharmacies to identify and evaluate which nutraceutical product codes to develop to add to our SkyPremium Life portfolio. We intend to continue to bring SkyPremium Life products to market primarily through our existing network of over 160 pharmaceutical wholesale clients and vendors and approximately 370 independent retail pharmacies in the EU. There is growing demand for vitamins and food supplements and we are committed to developing quality products and creating enhanced customer value.

We are also closely monitoring the legal framework for prescription and non-prescription ~~derivates~~derivatives of cannabis products as it develops in Europe. As the legal framework and processes are developed and implemented in each respective EU country, we ~~will~~intend to utilize our existing network to distribute both prescription and non-prescription derivatives of cannabis products to our current customer base. We currently intend to only distribute prescription and non-prescription derivatives of cannabis products to approved EU countries and not in the US.

We regularly evaluate acquisition targets that would allow us to expand our distribution reach and/or vertically integrate into the supply chain of the products that we currently distribute. We believe that the demand for reasonably priced medicines, delivered on time and in the highest quality is set to increase in the years to come, as the population’s life expectancy increases. With our product portfolio of patented and non-patented medicines, we contribute to the optimization of efficient medicinal care, and thereby lowering cost for health insurance funds, companies, and patients. We also believe that the demand for non-prescription wellness products such as food and dietary supplements will continue to increase as individuals are increasingly supplementing their nutritional intake.

We believe the EU pharmaceutical import/export market will continue to grow. We continue to encounter competition in the market as we grow. The competition comes in the form of level of service, reliability, and product quality. On the procurement side, we continue to expand our vendor base. In order to minimize business risks, we diversify our sources of supply. We maintain our high-quality standards by carefully selecting and qualifying our suppliers, as well as actively ensuring that our suppliers meet our standard of quality control on an ongoing basis.

On July 22, 2015, the Hellenic Ministry of Health and more specifically the National Organization for Medicines granted SkyPharm a license for the wholesale of pharmaceutical products for human use. The license is valid for a period of five years and pursuant to the EU directive of (2013/C343/01). Pursuant to the EU directive of (2013/C 343/01), the Company is subject to fulfill the Guidelines of the Good Distribution Practices of medical products for human use. The Company submitted its application for renewal one month before the license expiration to the Hellenic Republic National Organization, but according to the EMA (eudragmdp.ema.europa.eu/inspections/view/wda/WDAHomePage.xhtml): “Due to the restrictions caused by COVID-19, the period of validity of MIA’s, WDA’s, GMP and GDP certificates is automatically extended until the end of 2021. On-site inspections will resume as soon as there is a consensus that the period of the public health crisis has passed. The clarifying remark section of individual MIA’s, WDA’s, GMP and GDP certificates will indicate any exceptions. Competent authorities reserve the right to inspect a manufacturing site should the need arise.” Therefore, the Company is eligible to continue its operations until the end of 2021.

Decahedron received its Wholesale Distribution Authorization for human use on November 7, 2013, from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in accordance with Regulation 18 of the Human Medicines Regulations 2012 (SI 2012/1916) and it is subject to the provision of those Regulations and the Medicines Act 1971. This license will continue to remain in force from the date of issue by the Licensing Authority unless cancelled, suspended, revoked or varied as to the period of its validity or relinquished by the authorization holder.

~~On February 1, 2019,~~Our subsidiaries are ISO 9001 certified for a management system for the ~~Hellenic Ministry~~trade and distribution of ~~Health and~~pharmaceuticals. As part of the ~~National~~certification process by the International Organization for ~~Medicines extended~~Standardization, we need to be compliant with the ~~validity of Cosmofarm’s license for~~General Data Protection Regulation (GDPR) adopted by the ~~wholesale of pharmaceutical products for human use for a period of five years and pursuant~~European Union. GDPR applies to the processing of personal data of persons in the EU ~~directive~~by a controller or processor neither of ~~(2013/C 343/01).~~which apply to our operations.

Cosmos Holdings, Inc. was incorporated in the State of Nevada under the name Prime Estates and Developments, Inc. on July 21, 2009. On November 14, 2013, we changed our name to Cosmos Holdings, Inc.

On September 27, 2013, the Company, closed a reverse ~~take-over~~merger transaction by which it acquired a private company whose principal activities are the trading of products, providing representation, and provision of consulting services to various sectors. Pursuant to a Share Exchange Agreement between the Registrant and Amplerissimo Ltd., a company incorporated in Cyprus (“Amplerissimo”), the Company acquired 100% of Amplerissimo’s issued and outstanding common stock. As a result of the reverse take-over transaction, Amplerissimo became a wholly owned subsidiary of the Company.

On August 1, 2014, the Company, through its Cypriot subsidiary Amplerissimo, formed SkyPharm S.A., a Greek corporation (“SkyPharm”), a subsidiary that focuses on the trading, sourcing and distribution of pharmaceutical products.

On August 1, 2014, the Company, through its Cypriot subsidiary Amplerissimo, formed SkyPharm S.A., a Greek Company (“SkyPharm”), a subsidiary that focuses on the trading, sourcing and distribution of pharmaceutical products.

In February 2017, the Company completed the acquisition of Decahedron Ltd., a UK ~~corporation~~Company (“Decahedron”) consummating the transactions contemplated by the Stock Purchase Agreement, dated November 17, 2016 as amended (the “Decahedron SPA”). Pursuant to the terms of the Decahedron SPA, the shareholders of Decahedron received an aggregate of 170,000 shares of common stock of the Company (the “Stock Consideration”), which were delivered following the closing in exchange for all of the ordinary shares of Decahedron for the stock consideration. Decahedron is a fully licensed wholesaler of pharmaceutical products and its primary activity is the distribution, import and export of pharmaceuticals.

On November 21, 2017, the Company effected a one-for-ten (1:10) reverse stock split whereby the Company decreased, by a ratio of one-for-ten (1:10) the number of issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, and warrants including all share and per-share data, for all amounts and periods presented in the consolidated financial statements.

On September 29, 2018, Amplerissimo transferred its remaining 22% investment in SkyPharm to the Company. The Company now holds 100% of the capital of SkyPharm as a ~~100%~~ wholly-owned subsidiary of the Company. On September 30, 2018, the Company entered into a Share Purchase Agreement with an unaffiliated third party and sold 100% of the issued capital of its subsidiary, Amplerissimo.

On December 19, 2018, the Company completed the purchase of all of the capital stock of Cosmofarm Ltd. (“Cosmofarm”), a pharmaceutical wholesaler based in Athens, Greece. The principal of the selling shareholder is Panagiotis Kozaris, who remained with Cosmofarm as a director and chief operating officer once it became a wholly owned subsidiary of the Company. Grigorios Siokas, the Company’s CEO, became the new CEO of Cosmofarm. Mr. Kozaris had no prior relationship to the Company other than as an independent shareholder. The purchase price payable is €200,000 evidenced by a promissory note.

The Company’s consolidated financial statements are prepared in conformity with U.S. GAAP, which contemplates the continuation of the Company as a going concern. For the three months ended March 31, ~~2020,~~2021, the Company had revenue of ~~$11,933,248, a~~$11,619,076, net loss of ~~$483,310~~$2,173,903 and net cash used in operations of ~~$1,144,739.~~$665,339. Additionally, as of March 31, ~~2020,~~2021, the Company had working capital of $6,817,608, an accumulated deficit of ~~$20,054,920 a working capital deficit of $7,673,520~~$20,924,727, and stockholders’ deficit of ~~$7,087,901.~~$2,804,680. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date of this filing.

The ~~condensed~~Company has undergone strategic review processes to help find a definitive solution to the Company’s accumulated deficit constraints. Options under consideration in the strategic review process include, but are not limited to, securing new debt, exchange debt to equity, restructuring current debt facilities from short term to long term and making the proper actions for new fund raising.

The consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty.

The ~~Company has not yet established an adequate ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The~~ ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund ~~operating losses until it becomes profitable.~~its operations. If the Company is unable to obtain adequate capital, it could be forced to cease development of operations.

In order to continue as a going concern, develop a reliable source of revenues, and achieve a profitable level of operations, the Company will need, among other things, additional capital resources. Management’s plans to continue as a going concern include raising additional capital through increased sales of product and by sale of equity and/or debt. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described herein and eventually secure other sources of financing and attain profitable operations.

The accompanying condensed consolidated financial statements have been prepared in accordance with principles generally accepted in the United States of America.

Our condensed consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, SkyPharm S.A., Decahedron Ltd. and Cosmofarm Ltd. All significant intercompany balances and transactions have been eliminated.

The preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of May ~~15, 2020,~~17, 2021, the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur, and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.

For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of March 31, ~~2020,~~2021, and December 31, ~~2019,~~2020, there were no cash equivalents.

The Company maintains bank accounts in the United States denominated in U.S. Dollars and in Greece and in Bulgaria all of them denominated in Euros. The Company also maintains bank accounts in the United Kingdom of Great Britain, dominated in Euros and Great Britain Pounds (British Pounds Sterling).

Certain reclassifications have been made in the Company’s financial statements of the prior period to conform to the current year presentation. For the three the three months ended March 31, 2020, $53,729 in sales and marketing expenses were reclassified from general and administrative expenses. Additionally, for the three months ended March 31, 2020, $188,923 was reclassified from accounts payable and accrued expenses to accrued interest on the Statement of Cash Flows. These reclassifications have no impact on previously reported net income.

Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the ~~receivables~~receivables’ portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. As of March 31, ~~2020,~~2021, and December 31, ~~2019,~~2020, the Company’s allowance for doubtful accounts was ~~$551,723~~$687,340 and ~~$562,444,~~$715,845, respectively.

The Company pays Value Added Tax (“VAT”) or similar taxes (“input VAT”), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (“output VAT”) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. The net VAT receivable is recorded in prepaid expense and other current assets on the condensed consolidated balance sheets.

Inventory is stated at ~~the lower-of-cost or~~ net realizable value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e., packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment.

The Company ~~writes-down~~writes down inventories to net realizable value based on physical condition, expiration date, current market conditions, as well as forecasted demand. The Company’s inventories are not highly susceptible to obsolescence. Many of the Company’s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met.

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows:

Depreciation expense was ~~$53,512~~$71,471 and ~~$49,499~~$53,512 for the three months ended March 31, ~~2020~~2021 and ~~2019,~~2020, respectively.

In accordance with ASC 360-10, ~~Long-lived~~long-lived assets, property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.

The Company periodically reviews the carrying value of intangible assets not subject to amortization, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit.

Prior to the acquisition of Decahedron, the Company had no recorded goodwill value. As a result of the acquisition of Decahedron, the Company tested and expensed 100% of the goodwill allocated to the purchase price, an amount equal to $1,949,884 for the year ended December 31, 2017.

On December 19, 2018, as a result of the acquisition of Cosmofarm, the Company recorded $49,697 of goodwill.

Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for an import/export license. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. As of March 31, ~~2020,~~2021, no revision to the remaining amortization period of the intangible assets was made.

Amortization expense was ~~$8,248~~$8,158 and ~~$6,874~~$8,248 for the three months ended March 31, ~~2020~~2021 and ~~2019,~~2020, respectively.

For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company ~~records~~will record its share in the earnings of the investee and ~~is included in “Equity earnings of affiliate” in~~will include it within the condensed consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value.

Effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) 2016-01, and accordingly, investments in equity securities are accounted for at fair value with changes in fair value recognized in net ~~income.~~income (loss). Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for use in current operations are reported as a component of current assets in the accompanying consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets in the accompanying consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment.

As of March 31, ~~2020,~~2021, investments consisted of 3,000,000 shares, which traded at a closing price of ~~$0.005~~$0 per share or a value of ~~$14,100~~$0 of ICC International Cannabis Corp, 40,000 shares which traded at a closing price of ~~$4.91~~$5.24 per share, or value of ~~$196,525~~$209,495 of Diversa S.A. and 16,666 shares which traded at a closing price of ~~$0.33~~$0.29 per share or value of ~~$2,275~~$4,854 of National Bank of Greece. Additionally, the Company has ~~$4,298~~$4,582 in equity securities of Pancreta bank, which are not publicly traded and recorded at cost. See Note 3, for additional investments in equity securities.

The Company applies FASB ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements.

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

The following tables presents assets that are measured and recognized at fair value as of March 31, ~~2020~~2021 and December 31, ~~2019,~~2020, on a recurring basis:

In addition, FASB ASC 825-10-25, Fair Value Option, (“ASC 825-10-25”), expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments.

The Company receives prepayments from certain customers for pharmaceutical products prior to those customers taking possession of the Company’s products; the Company records these receipts as customer advances until it has met all the criteria for recognition of revenue including passing control of the products to its customer, at such point the Company will reduce the customer and deposits balance and credit the Company’s revenues.

~~The Company adopted the modified retrospective adoption in~~In accordance with ASC 606, Revenue from Contracts with Customers, ~~on January 1, 2018. The new guidance introduces~~the Company uses a five-step model for recognizing revenue by applying the following steps: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligations are satisfied by transferring the promised goods to the customer. Once these steps are met, revenue is recognized upon ~~delivery~~transfer of the ~~product. Adoption of ASC 606 has not changed~~product to the ~~timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s condensed consolidated financial statements.~~customer.

The Company records stock-based compensation in accordance with ASC 718, Stock Compensation (“ASC 718”) and Staff Accounting Bulletin No. 107 (“SAB 107”) issued by the SEC in March 2005 regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model.

The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASU 2018-07, ~~Compensation-Stock Compensation.~~“Compensation-Stock Compensation-Improvements to Nonemployee Share-Based Payment Accounting.”

Assets and liabilities of all foreign operations are translated at year-end rates of exchange, and the statements of operations are translated at the average rates of exchange for the year. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders’ deficit until the entity is sold or substantially liquidated.

Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity’s local currency) are included in net earnings.

The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company is liable for income taxes in Greece and the United Kingdom of England. The corporate income tax rate is ~~29%~~22% in Greece (tax losses are carried forward for five years effective January 1, 2013) and ~~20%~~19% in United Kingdom of England. Losses may also be subject to limitation under certain rules regarding change of ownership.

We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. ~~As of~~At March 31, ~~2020,~~2021 the Company has maintained a valuation allowance against all net deferred tax assets in each jurisdiction in which it is subject to income tax.

The Company periodically reviews the uncertainties and judgments related to the application of complex income tax regulations to determine income tax liabilities in several jurisdictions. The Company uses a “more likely than not” criterion for recognizing the income tax benefit of uncertain tax positions and establishing measurement criteria for income tax benefits. The Company has evaluated the impact of these positions and due to the fact that the fiscal years 2013 - 2014 are unaudited by the Greek tax authorities, a potential tax liability has not been identified ~~which may arise from~~because there is a limitation on periods that the Tax authorities can audit retrospectively 5 years prior to the current fiscal year. Therefore, no prospective tax audit from tax authorities based on the tax settlement note of years 2007 - 2009. The amount of the liability as of March 31, 2020, and December 31, 2019, was $78,196 and $79,716, respectively, and has been recorded as a long-term liability within the condensed consolidated balance sheets.may arise.

Under Greek labor law, employees are entitled to lump-sum compensation in the event of termination or retirement. The amount depends on the employee’s work experience and renumeration as of the day of termination or retirement. If an employee remains with the company until full-benefit retirement, the employee is entitled to a lump-sum equal to 40% of the compensation to be received if the employee were to be dismissed on the same day. The Company periodically reviews the uncertainties and judgments related to the application of the relevant labor law regulations to determine retirement and termination benefits obligations of its Greek subsidiaries. The Company has evaluated the impact of these regulations and has identified a potential retirement and termination benefits liability. The amount of the liability as of March 31, ~~2020,~~2021, and December 31, ~~2019,~~2020, was ~~$75,706~~$102,901 and ~~$77,170~~$107,167 respectively, and has been recorded as a long-term liability within the condensed consolidated balance sheets.

Basic income per share is calculated by dividing income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted income per share is calculated by dividing income available to common stockholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. In accordance with ASC 260, Earnings Per Share, the following table reconciles basic shares outstanding to fully diluted shares outstanding.

Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented.

In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350), which simplifies the measurement of goodwill by eliminating Step 2 from the current goodwill impairment test in the event that there is evidence of an impairment based on qualitative or quantitative assessments. ASU 2017-04 does not change how the goodwill impairment is identified, and the Company will continue to perform a qualitative assessment annually to determine whether the two-step impairment test is required. Until the adoption, current accounting standards require the impairment loss to be recognized under Step 2 of the impairment test. This requires the Company to calculate the implied fair value of goodwill by assigning fair value to the reporting unit’s assets and liabilities as if the reporting unit has been acquired in a business combination, then subsequently subtracting the implied goodwill from the carrying amount of the goodwill. The new standard would require the Company to determine the fair value of the reporting unit and subtract the carrying value from the fair value of the reporting unit to determine if there is an impairment. ASU 2017-04 is effective for the Company for fiscal years beginning after December 15, 2019, and early adoption is permitted. ASU 2017-04 is required to be adopted prospectively, and the adoption is effective for annual goodwill impairment tests performed in the year of adoption. The adoption of ASU No. 2017-04 did not have a material effect on the Company’s condensed consolidated financial position or the Company’s consolidated results of operations.

In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) ”Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated financial statements.

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial statements.

On March 19, 2018, the Company entered into a Distribution and Equity Acquisition Agreement (the “Distribution and Equity Acquisition Agreement”) with Marathon Global Inc. (“Marathon”), a company incorporated in the Province of Ontario, Canada. Marathon was formed to be a global supplier of cannabis, cannabidiol (CBD) and/or any cannabis extract products, extracts, ancillaries and derivatives (collectively, the “Products”). The Company was appointed the exclusive distributor of the Products initially throughout Europe and on a non-exclusive basis wherever else lawfully permitted. The Company has no present intention to distribute any Products under this Agreement in the United States or otherwise participate in cannabis operations in the United States. The Company intends to await further clarification from the U.S. Government on cannabis regulation prior to determining whether to enter the domestic market.

The Distribution and Equity Acquisition Agreement is to remain in effect indefinitely unless Marathon fails to provide Market Competitive (as defined) product pricing and Marathon has not become profitable within five (5) years of the agreement. The transaction closed on May 22, 2018 after the due diligence period, following which the Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it fails to meet certain performance milestones. The Company is entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000. The Company was also given the right to nominate one director to the Marathon board of directors.

Since Marathon was a newly formed entity with no assets and no activity, the Company attributed no value to the 5 million shares in Marathon which was received as consideration for the distribution services. As described below, the Company exchanged the Marathon shares in May and July 2018.

On May 17, 2018, the Company entered into a Share Exchange Agreement (the “SEA”) with Marathon, ICC International Cannabis Corp (“ICC”) formerly known as Kaneh Bosm Biotechnology Inc. (“KBB”) and certain other sellers of Marathon capital stock. Under the SEA, the Company transferred 2.5 million shares in Marathon to ICC, a corporation incorporated under the laws of the Province of British Columbia and a public reporting issuer on the Canadian Securities Exchange, in exchange for 5 million shares of ICC. The Company accounted for the exchange at fair value and recognized a gain on exchange of its investment in Marathon of $1,953,000 in the year ended December 31, 2018.

On July 16, 2018, the Company completed a Share Exchange Agreement (the “New SEA”) with Marathon, ICC, and certain other sellers of Marathon capital stock whereby the Company transferred its remaining one-half interest (2.5 million shares) in Marathon to KBB for an additional 5 million shares of ICC. The Company accounted for the exchange at fair value and recognized a gain on exchange of its investment in Marathon of $2,092,200 in the year ended December 31, 2018. The ten million shares of ICC owned by the Company constituted approximately 7% of the 141,219,108 shares of capital stock of KBB then issued and outstanding. The Company does not have the ability to exercise significant influence over ICC.

The Company determined the fair value of both exchanges based on an actively quoted stock price of ICC received in exchange for the Marathon shares. The Company continues to fair value its investment in ICC with changes recognized in earnings each period and was recorded as an unrealized ~~loss~~gain on exchange of investment during the three months ended March 31, ~~2020~~2021 of ~~$18,900.~~$0. The value of the investments as of March 31, ~~2020~~2021 and December 31, ~~2019,~~2020, was ~~$14,100~~$0 and ~~$33,000,~~$0, respectively.

Since no value was attributed to the 33 1/3% equity ownership interest in Marathon received as consideration for the distribution services, the Company would receive variable consideration in future for its services under the Distribution and Equity Acquisition Agreement, if certain milestones are achieved. Refer to Note 11 for the accounting associated with the cash of CAD $2 million received upfront. Variable consideration to be received in the future upon achieving the gross sales milestones described above, is constrained as the Company estimates that it is probable that a significant reversal of revenue could occur. In assessing the constraint, the Company considered its limited experience with the Products, new geographic markets and similar transactions, which affect the Company’s ability to estimate the likelihood of a probable revenue reversal. Therefore, no revenue has been recognized for the period ended March 31, ~~2020.~~2021. The Company will continue to reassess variable consideration at each reporting period and update the transaction price when it becomes probable that a significant revenue reversal would not occur.

As of March 31, ~~2020,~~2021, in addition to the 3,000,000 ICC shares valued at ~~$14,100,~~$0, as noted above, marketable securities also consisted of the following: 40,000 shares which traded at a closing price of ~~$4.91~~$5.24 per share, or value of ~~$196,525~~$209,495 of Diversa S.A. and 16,666 shares which traded at a closing price of ~~$0.33~~$0.29 per share or value of ~~$2,275~~$4,854 of National Bank of Greece. The Company recorded a net unrealized ~~loss~~gain on the fair value of these investments of ~~$3,272~~$440 during the three months ended March 31, ~~2020.~~2021.

In June 2019, the Company entered into an agreement with an unaffiliated third party to incorporate CosmoFarmacy L.P. for the purpose of providing strategic management consulting services and the retail trade of pharmaceutical products, and OTC to pharmacies. CosmoFarmacy was incorporated with a 30-year term through May 31, 2049. The unaffiliated third party is the general partner (the “GP”) of the limited partnership and is responsible for management and decision-making associated with CosmoFarmacy. The initial share capital was set to EUR 150,000 which was later increased to EUR 500,000. The GP contributed the pharmacy license (the “License”) valued at EUR 350,000 (30-year term) to operate the business of CosmoFarmacy in exchange for a 70% equity ownership. The Company is a limited partner and contributed cash of EUR 150,000 for the remaining 30% equity ownership. CosmoFarmacy is not publicly traded and the Company’s investment has been recorded using the equity method of accounting. The value of the investment as of March 31, ~~2020~~2021 was ~~$165,195.~~$176,145 and is included in “Other assets” on the Company’s condensed consolidated balance sheet.

The Company is incorporated in the United States of America and is subject to United States federal taxation. No provisions for income taxes have been made as the Company had no U.S. taxable income for the three months ended March 31, ~~2020~~2021 and ~~2019.~~2020.

The Company’s Greece subsidiaries are governed by the income tax laws of Greece. The corporate tax rate in Greece is ~~29%~~22% on income reported in the statutory financial statements after appropriate tax adjustments.

The Company’s United Kingdom subsidiaries are governed by the income tax laws of the United Kingdom. The corporate tax rate in the United Kingdom is 19% on income reported in the statutory financial statements after appropriate tax adjustments.

On December 22, 2017, the President of the United States signed into law Public Law No. 115-97, commonly referred to as the Tax Reform Act, following its passage by the United States Congress. The Tax Reform Act made significant changes to U.S. federal income tax laws, including reduction of the corporate tax rate from 34.0% to 21.0%, limitation of the deduction for net operating losses to 80.0% of current year taxable income and elimination of net operating loss carrybacks, one-time taxation of offshore earning at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions.

On December 22, 2017, Staff Accounting Bulletin No. 118, “SAB 118”, was issued to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. Additional work is necessary for a more detailed analysis of the deferred tax assets and liabilities and our historical foreign earnings as well as potential correlative adjustments. Any subsequent adjustment to these amounts will be recorded to current tax expense within the measurement period.

As of March 31, ~~2020~~2021, and ~~2019,~~2020, the Company’s effective tax rate differs from the US federal statutory tax rate primarily due to a valuation allowance recorded against net deferred tax assets in ~~all jurisdictions~~ in ~~which~~ the ~~Company operates.~~United States.

We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. As of March 31, ~~2020,~~2021 and December 31, ~~2019,~~2020, the Company has maintained a valuation allowance against all net deferred tax assets in ~~each jurisdiction in which it is subject to income tax.~~the United States only. Foreign valuation allowances had been reversed at December 31, 2020.

As of March 31, ~~2020,~~2021, and December 31, ~~2019,~~2020, the Company has a ~~provision~~benefit for tax ~~charges~~ recorded in any jurisdiction where it is subject to income tax, in the amount of ~~$78,196~~$499,368 and ~~$79,716,~~$178,430, respectively, which is included in ~~Other Liabilities~~Deferred tax assets, on the condensed consolidated balance sheets.

The Company is authorized to issue 100 million shares of preferred stock, which may be issued from time to time in one or more series authorized by the Board of Directors. As of March 31, ~~2020,~~2021, no preferred shares have been issued.

The Company is authorized to issue 300 million shares of common stock. As of March 31, ~~2020~~2021 and December 31, ~~2019,~~2020, the Company had ~~13,225,387~~16,066,947 and ~~13,225,387~~13,485,128 shares of our common stock issued and ~~12,860,059~~15,716,619 and ~~12,860,059~~13,069,800 shares outstanding, respectively.

On ~~February 18, 2019,~~July 31, 2020, the Company entered into a Stock Purchase Agreement (the ~~“SPA”~~“July SPA”) with ~~an institutional noteholder.~~a shareholder. The July SPA provides for the Company’s purchase of ~~83,341~~10,000 shares of the Company’s common stock at ~~$3.00~~$4.00 per share or an aggregate of ~~$250,023. Payment was scheduled over a five-month period, subject to acceleration, if the Company effects an eligible equity offering.~~$40,000. As of December 31, ~~2019,~~2020, the Company ~~had~~ made ~~$250,023~~$40,000 in payments.

On August 31, 2020, the Company entered into two Stock Purchase Agreements (the “August SPAs”) with a shareholder. The August SPAs provide for the Company’s purchase of an aggregate total of 10,000 shares of the Company’s common stock at $4.00 per share or an aggregate of $40,000. As of December 31, 2020, the Company made $40,000 in payments.

On September 30, 2020, the Company entered into a Stock Purchase Agreement (the “July SPA”) with a shareholder. The July SPA provides for the Company’s purchase of 10,000 shares of the Company’s common stock at $4.00 per share or an aggregate of $40,000. As of December 31, 2020, the Company made $40,000 in payments.

On October 31, 2020, the Company entered into a Stock Purchase Agreement (the “July SPA”) with a shareholder. The July SPA provides for the Company’s purchase of 10,000 shares of the Company’s common stock at $4.00 per share or an aggregate of $40,000. As of December 31, 2020, the Company made $40,000 in payments.

On November 30, 2020, the Company entered into a Stock Purchase Agreement (the “July SPA”) with a shareholder. The July SPA provides for the Company’s purchase of 10,000 shares of the Company’s common stock at $4.00 per share or an aggregate of $40,000. As of December 31, 2020, the Company made $40,000 in payments.

On February 5, 2021, the Company entered into a Stock Purchase Agreement (the “February SPA”) with an unaffiliated third-party. The February SPA provides for the Company’s to sell 65,000 shares of the Company’s common stock held in treasury at $3.85 per share or a total of $250,000.

The Company entered into a Consulting Agreement (the “Agreement”) effective as of February 5, 2021, with a non-affiliated consultant (the “Consultant”). The Company engaged the Consultant to perform consulting services relating to Company management, debt structure, business plans and business development in connection with any capitalization transactions involving the Company and any newly created or existing entities. The Agreement is for a term of nine (9) months with an initial term of ninety (90) days (the “Initial Term”). The Agreement is terminable by the Company for any reason upon written notice at any time after the Initial Term.

The Company agreed to pay Consultant and its assignees an aggregate of 1,800,000 restricted shares of Common Stock, earned at the rate of 200,000 shares per month, which shall be issued and fully paid for in consideration of the Consultant’s considerable expertise and experience and its commitment to work for the Company. However, in the event the Agreement is terminated for any reason after the Initial Term, the shares are subject to a claw back for any months remaining after the Termination Date. The Consultant retained 800,000 of the 1,800,000 shares and agreed with an assignee and the Company that 1,600,000 of the 1,800,000 shares shall be held in book entry for six (6) months from the date of this ~~filing, 26,221 shares have been transferred back~~Agreement, subject to the ~~Company and subsequently cancelled. An additional 57,120 have been transferred to~~above claw back. The shares valued on the date of the agreement at $3.28 per share or $5,904,000, which will be amortized over the term of the agreement. As of March 31, 2021, the Company ~~have not yet been cancelled and are~~has recorded $1,189,451 in ~~treasury.~~stock-based compensation for the 400,000 shares earned through the end of the period.

No options, warrants or other potentially dilutive securities have been issued as of March 31, ~~2020.~~2021 and December 31, 2020, respectively.

On the date of our inception, we issued 2 million shares of our common stock to our three officers and directors which were recorded at no value (offsetting increases and decreases in common stock and additional paid-in capital).

As of March 31, ~~2020,~~2021, the Company has a prepaid balance of ~~€2,127,745 ($2,343,924)~~$3,522,041 and an accounts payable balance of ~~€30,526 ($33,627),~~$27,453, resulting in a net prepaid balance of ~~€2,097,219 ($2,310,296)~~$3,494,588 to Doc Pharma S.A. related to purchases of inventory. Additionally, the Company has a receivable balance of ~~€326,696 and £168,633 ($569,903).~~$3,247,612. As of December 31, ~~2019,~~2020, the Company has a prepaid balance of ~~€2,181,780 ($2,403,449) and an accounts payable balance of €22,576 ($24,870), resulting in a net prepaid balance of €2,158,434 ($2,377,731)~~$3,468,653 to Doc Pharma S.A. related to purchases of inventory. Additionally, the Company ~~has~~had a receivable balance of ~~€546,240 ($601,738).~~$3,468,564.

During the three months ended March 31, ~~2020~~2021 and ~~2019,~~2020, the Company ~~has~~ purchased a total of ~~€608,448 ($670,631) €507,389 ($576,089)~~$589,261 and $670,631 of products from Doc Pharma S.A., respectively. During the three months ended March 31, 2021 and 2020 the Company had $290,598 and ~~2019, Skypharm and Cosmofarm had €132,368 ($145,896) €158,828 ($183,333)~~$261,543 in revenue from Doc Pharma ~~and Decahedron had revenue £168,633 ($215,648) from Doc Pharma,~~S.A., respectively.

Doc Pharma S.A is considered a related party to the Company due to the fact that the CEO of Doc Pharma is the wife of Grigorios Siokas, the Company’s CEO and principal shareholder, who also served as a principal of Doc Pharma SAS.A. in the past.

A summary of the Company’s related party notes payable ~~during the three months ended~~as of March 31, ~~2020~~2021 and ~~the year ended~~ December 31, ~~2019~~2020 is presented below:

	2020			2019			2021			2020

Beginning Balance	$	1,375,532		$	1,793,437		$	501,675		$	1,375,532
Payments		(3,305	)		(382,055	)		-			(996,136	)
Foreign currency translation		(25,851	)		(35,850	)		(19,977	)		122,279
Ending Balance	$	1,346,376		$	1,375,532		$	481,698		$	501,675

On December 20, 2018, the €1,500,000 ($1,718,400) note payable, originally borrowed pursuant to a Loan Agreement with a third-party lender, dated March 16, 2018, was transferred to Grigorios Siokas. The note bears an interest rate of 4.7% per annum and ~~has a~~matured on March 18, 2019 pursuant to the original agreement. The note is not in default and the maturity date ~~of March 18, 2019.~~has been extended until December 31, 2021. As of December 31, ~~2019,~~2020, the note had an outstanding principal balance of ~~€1,200,000~~€400,000 ($~~1,347,240)~~489,200) and accrued interest of ~~€124,281~~€158,287 ($~~139,530)~~193,585). As of March 31, ~~2020,~~2021, the Company has an outstanding balance of ~~€1,200,000~~€400,000 ($~~1,321,920)~~469,720) and accrued interest of ~~€138,345~~€198,220 ($~~152,401)~~232,770).

On November 21, 2014, the Company entered into an agreement with Dimitrios Goulielmos, as amended on November 4, 2016. Pursuant to the amendment, this loan has no maturity date and is non-interest bearing. ~~During the year ended December 31, 2019, the Company repaid €40,300 ($45,245) and a principal balance of €13,200 ($14,820) remained as~~As of December ~~31, 2019. During the three months ended March~~ 31, 2020, the Company ~~repaid €3,000 ($3,305) and~~had a principal balance of €10,200 ($~~11,237)~~12,475). As March 31, 2021 a principal balance of €10,200 ($11,978) remained as of March 31, ~~2020.~~2021.

On November 1, 2015, the Company entered into a €12,000 ($12,662) Loan Agreement with Doc Pharma S.A, pursuant to which Doc Pharma S.A., paid existing bills of the Company in the amount of €12,000 ($12,662), excluding the Vendor Bills. The loan bears an interest rate of 2% per annum and was due and payable in full on October 31, 2016. As of December 31, 2019, the Company has an outstanding principal balance of €12,000 ($13,472) and accrued interest expense of $1,100. As of March 31, 2020, the Company has an outstanding principal balance of €12,000 ($13,219) and accrued interest expense of $1,166.

The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, ~~2020~~2021 the Company recorded ~~losses~~a loss of ~~$25,851.~~

A summary of the Company’s related party loans payable during the three months ended March 31, ~~2020,~~2021, and the year ended December 31, ~~2019~~2020 is presented below:

From time to time, Grigorios Siokas loans the Company funds in the form of non-interest bearing, no-term loans. As of December 31, ~~2019,~~2020, the Company had an outstanding principal balance under these loans of ~~$1,026,264 consisting of €297,314 ($303,502) and $722,762,~~$1,629,246 in loans payable to Grigorios Siokas. During the three months ended March 31, ~~2020,~~2021, the Company borrowed additional proceeds of ~~€124,200~~€169,000 ($~~136,819)~~198,865) and ~~$380,000~~$200,000 and repaid ~~€45,000~~€56,000 ($~~49,572)~~65,761) of these loans. As of March 31, ~~2020,~~2021, the Company had an outstanding balance under these loans of ~~$1,487,807.~~$1,941,773.

The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, ~~2020~~2021 the Company recorded ~~losses~~a loss of ~~$5,704.~~$20,577.

Except as set forth above, we have not entered into any material transactions with any director, executive officer, and promoter, beneficial owner of five percent or more of our common stock, or family members of such persons.

A summary of the Company’s lines of credit as of March 31, ~~2020~~2021 and December 31, ~~2019~~2020 is presented below:

	March 31, 2020		December 31, 2019		March 31, 2021		December 31, 2020
National	$	2,629,327	$	1,940,045	$	2,837,626	$	3,540,550
Alpha		805,678		810,947		1,088,358		1,106,894
Eurobank		-		-
Pancretan						364,550		-
National - COVID						489,592		429,240
Total	$	3,435,005	$	2,750,992	$	4,780,126	$	5,076,684

The line of credit with National Bank of Greece is being renewed annually with current interest rates of 6.00%, 4.35% (“COSME 2”) and 4.35% (plus the 6-month Euribor plus any contributions currently in force by law on certain lines of credit), (“COSME 1”). The maximum borrowing allowed for the 6% line of credit was $2,583,460 and $2,690,600 at March 31, 2021 and December 31, 2020, respectively for the 6% line of credit. The outstanding balance was $1,790,935 and $2,411,182 at March 31, 2021 and December 31, 2020, respectively.

The maximum borrowing allowed was ~~$1,651,950~~$1,174,300 and ~~$1,684,050~~$1,223,000 at March 31, ~~2020~~2021 and December 31, ~~2019, respectively for the 6.00% line of credit. The maximum borrowing allowed was $1,101,300 and $1,122,700 at March 31,~~ 2020, ~~and December 31, 2019,~~ respectively, for the 4.35% lines of credit. The outstanding balance was ~~$2,629,327~~$1,046,691 and ~~$1,940,045~~$1,129,368 at March 31, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively.

The line of credit with Alpha Bank of Greece is renewed annually with a current interest rate of 6.00%. The maximum borrowing allowed was ~~$1,101,300~~$1,174,300 and ~~$1,122,700~~$1,123,000 at March 31, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively. The outstanding balance was ~~$805,678~~$1,088,358 and ~~$810,947~~$1,106,894 at March 31, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively.

The Company entered into a line of credit with Pancreta bank on February 23,2021. The line of credit is renewed annually with a current interest rate of 6.10%. The maximum borrowing allowed was $587,150 at March 31, 2021. The outstanding balance was $364,550 at March 31, 2021.

Interest expense for the three months ended March 31, 2021 and 2020, was $16,501 and ~~2019, was~~ $17,673, ~~and $45,174,~~ respectively.

Under the agreements, the Company is required to maintain certain financial ratios and covenants. These lines of credit were assumed in the Company’s acquisition of Cosmofarm. During the three months ended March 31, ~~2020~~2021 and ~~2019,~~December 31, 2020, the Company was in compliance with these ratios and covenants.

~~Notes~~On June 23, 2020, the Company’s subsidiary, Cosmofarm, entered into an agreement with the “National Bank of Greece SA” (the “Bank”) to ~~Unaudited Condensed Consolidated Financial Statement~~

borrow a maximum of €500,000 ($611,500) under a proposed plan which will operate the same as the line of credit above. The proposed plan has a maturity date of sixty (60) months from the date of the first disbursement, which includes a grace period of nine months. The total amount of the initial proceeds were paid in 3 equal monthly installments. The line of credit is interest bearing from the date of receipt and is payable every three (3) months at an interest rate of 2.7%. The outstanding balance was $489,592 and $429,240 at March 31, ~~2020~~2021 and December 31, 2020.

A summary of the Company’s convertible debt during the three months ended March 31, ~~2020~~2021 and the year ended December 31, ~~2019~~2020 is presented below:

	2020			2019			2021			2020

Beginning balance notes		1,500,000			365,513			1,447,000			1,500,000
New notes		-			1,500,000			100,000			540,000
Payments		(100,000	)		(365,513	)		(180,000	)		(593,000	)
Subtotal notes		1,400,000			1,500,000			1,367,000			1,447,000
Debt discount at year end		-			(29,509	)		(507,483	)		(494,973	)
Note payable net of discount		1,400,000			1,470,491			859,517			952,027

All of the convertible debt is classified as short-term within the consolidated balance sheet as it all matures and will be paid back within fiscal year 2021.

On May 15, 2019, the Company entered into a Securities Purchase Agreement with an institutional investor (the “Buyer”). Upon the closing of this financing, on May 17, 2019, the Company issued for a purchase price of $1,500,000 in principal amount a Senior Convertible Note (the “May 2019 Note”) to the Buyer.

The May 2019 Note ~~provides~~provided that the Company will repay the principal amount of the May 2019 Note on or before March 15, 2020.

On March 23, 2020, the Company entered into a Forbearance and Amendment Agreement (the “Agreement”) with an institutional investor (the “Buyer”). The Agreement provides that the Buyer will (a) forbear (i) from taking any action with respect to the Existing Default and (ii) from issuing any demand for redemption of the Note on the basis of the Existing Default until the earlier of: (1): (September 16, 2020 (or, if earlier, such date when all amounts outstanding under the Note shall be paid in full or converted into shares of Common Stock in accordance therewith) and (2) the time of any breach by the Company of the Agreement or the occurrence of an Event of Default that is not an Existing Default (the “Forbearance Expiration Date”), (b) during the Forbearance Period waive the prepayment premium to any Company Optional Redemption, and (c) during the Forbearance Period, waive the repayment in full of the Note other than the Required Payments (as defined) prior to September 16, 2020. The Scheduled Required Prepayments are $100,000 upon signing the Agreement and five (5) monthly payments thereafter aggregating $200,000 with all amounts outstanding under the Note due on September 16, 2020. In addition, there are mandatory prepayments in the event the Company completes a Subsequent Placement (as defined) or long-term debt (other than from the Buyer or from officers and directors and advisors of the Company) or factoring and purchase order indebtedness, the Company shall effect a Company Optional Redemption amount equal to 50% of the gross proceeds (less reasonable expenses of counsel and any investment bank) together with all Scheduled Required Payments.

On September 23, 2020, the Company entered into a Second Forbearance and Amendment Agreement (the “Agreement”) with an institutional investor (the “Buyer”). The Company entered into a Securities Purchase Agreement (the “SPA”) with the Buyer on May 15, 2019, pursuant to which the Company issued a Convertible Note (the “Note”) in the principal amount of $1,500,000. On March 23, 2020, the Company entered into a Forbearance and Amendment Agreement. The Note was due to be paid in full on or before ~~March 15,~~September 16, 2020 and was not paid (the “Existing Default”). The Note provides that upon an Event of Default, the Buyer may, among other things, require the Company to redeem all or a portion of the Note at a redemption premium of 120%, multiplied by the product of the conversion rate ($6.00per share) and the then current market price.

The Agreement provides that the Buyer will (a) forbear (i) from taking any action with respect to the Existing Default and (ii) from issuing any demand for redemption of the Note on the basis of the Existing Default until the earlier of: (1): ~~(September~~June 16, ~~2020~~2021 (or, if earlier, such date when all amounts outstanding under the Note shall be paid in full or converted into shares of Common Stock in accordance therewith) and (2) the time of any breach by the Company of the Agreement or the occurrence of an Event of Default that is not an Existing Default (the “Forbearance Expiration Date), (b)during the Forbearance Period (as defined) waive the prepayment premium to any Company Optional Redemption (which will result in the 120% redemption premium effectively replaced with 100%), and (c) during the Forbearance Period, waive the repayment in full of the Note other than the Required Payments (as defined) prior to ~~September~~June 16, ~~2020.~~2021. The Scheduled Required Prepayments are ~~$100,000~~$63,000 upon signing the Agreement and ~~five (5)~~eight (8) monthly payments thereafter aggregating ~~$200,000~~$480,000 with ~~all amounts~~the remaining $607,000 outstanding under the Note due on ~~September~~June 16, ~~2020.~~2021. In addition, there are mandatory prepayments in the event the Company completes a Subsequent Placement (as defined) or long-term debt (other than from the Buyer or from officers, ~~and~~ directors and ~~advisors~~10% or greater shareholders of the Company) or factoring and purchase order indebtedness, the Company shall effect a Company Optional Redemption amount equal to 50% of the gross proceeds (less reasonable expenses of counsel and any investment bank) together with all Scheduled Required Payments.

The May 2019 Note is convertible at any time by the Holder into 250,000 shares of common stock, par value $0.001 per share at the rate of $6.00 per share, subject to adjustment (the “Conversion Price”). Upon an Event of Default (regardless of whether such event has been cured), the Buyer may convert at an alternative conversion price equal to the lower of the then applicable Conversion Price or seventy-five (75%) percent of the then Volume-Weighted Average Price (as defined, the “VWAP”). The Company considered the need for the conversion feature to be bifurcated under ASC 815 and determined that it does not meet the requirements. Additionally, the Company determined the effective conversion rate under ASC 470-20 and determined that the instrument is out of the money and no beneficial conversion feature was recorded.

The May 2019 Note is senior in right of payment to all other existing and future indebtedness of the Company except Permitted Senior Indebtedness (as defined in the May 2019 Note), including $12 million of senior secured indebtedness of the Company and its subsidiaries under an existing senior loan agreement, plus defined amounts of purchase money indebtedness in connection with bona fide acquisitions.

The May 2019 Note includes customary Events of Default and provides that the Buyer may require the Company to redeem (regardless of whether the Event of Default has been cured) all or a portion of the Note at a redemption premium equal to the greater of: (i) the product of the redemption premium of one hundred twenty-five (125%) percent, multiplied by the ~~greater~~conversion amount, and (ii) the product of the conversion rate ~~and~~($6.00 per share) multiplied by the product of 125% multiplied by the then current market price. The Buyer may also require redemption of the May 2019 Note upon a Change of Control (as defined) at a premium of one hundred twenty-five (125%) percent. The Company has the right to redeem the May 2019 Note at any time, in whole or in part, in cash at a price equal to 120% of the then outstanding conversion amount.

Conversion of the May 2019 Note is subject to a blocker provision which prevents any holder from converting the May 2019 Note into shares of common stock if its beneficial ownership of the common stock would exceed 9.99% of the Company’s issued and outstanding common stock.

~~During the three months ended March~~As of December 31, ~~2020, the Company repaid $100,000 such that as of March 31, 2020,~~2019, the Company had a principal balance ~~$1,400,000~~of $907,000 on the May 2019 Note and the Company had accrued ~~$24,859~~$15,420 in interest expense. During the three months ended March 31, 2021, the Company repaid $180,000 such that as of March 31, 2021, the Company had a principal balance $727,000 on the May 2019 Note and the Company had accrued $12,849 in interest expense.

Roth Capital Partners, LLC (“Roth”), as the Company’s exclusive placement agent, received a cash commission for this transaction equal to six (6%) percent of the total gross proceeds of the offering. This 6% fee or $90,000 was recorded as debt discount along with the $30,000 in legal fees associated with the May 2019 Note. These fees will be amortized over the term of the note. The Company amortized $90,491 in the year ended December 31, 2019 and the remaining $29,509 was amortized during the year ended December 31, 2020.

On December 21, 2020 (the “Issue Date”), Cosmos Holdings, Inc. (“Cosmos”, the “Borrower” or the “Company”) entered into a convertible promissory note with Platinum Point Capital, LLC (the “Holder”, “Lender” or “Platinum”).

The Company issued the $540,000 Note in exchange for $500,000 in cash and included a $40,000 Original Issue Discount (“OID”) and paid $3,000 in financing costs. The principal amount together with interest at the rate of eight percent (8.0%) per annum, compounded annually (the “Interest Rate”), will be paid to the Lenders on or before the Maturity Date (December 31, 2021 or as defined below). Accrued interest shall be calculated on the basis of a 360-day year for the actual number of days elapsed. In the event that on or before the Maturity Date, the Note either (i) have not been converted or have not been otherwise satisfied in full or (ii) an Event of Default occurs, then the applicable rate of interest on the outstanding amount of the Note since inception shall be the Interest Rate plus eighteen percent (18.0%), the Default Interest. Unless previously converted, the principal and accrued interest on the Note is due and payable in cash (USD) upon the earlier of (i) December 31, 2021, (ii) a Change of Control (as defined below) or (iii), an Event of Default (as defined below) (collectively, the “Maturity Date”). As of March 31, 2021, the Company had a principal balance of $540,000 and had accrued $12,600 in interest expense.

The Note may be prepaid in whole or part beginning from the issue date until a date not later than 180 days thereafter, the Company shall have the right to prepay the full amount outstanding under the Note (principal and accrued interest), in full by making a payment to the Holder in an amount equal to one hundred twenty (120%) multiplied by the sum of (w) the then outstanding principal amount of this Note plus (x) accrued and unpaid interest on the unpaid principal amount of the Note plus (y) Default Interest, if any.

The Holder shall have the right at any time from the Issue Date to convert all or part of the outstanding and unpaid principal amount of the Note into Common Stock at the Conversion Price of as defined below.

The Company determined that the embedded conversion feature of the convertible promissory note meets the definition of a beneficial conversion feature and a derivative liability which is accounted for separately. The Company measured the beneficial conversion feature’s intrinsic value on December 16, 2020 and determined that the embedded derivative was valued at $456,570 which was recorded as a debt discount, and together with the original issue discount and transaction expenses of $43,000, in the aggregate of $499,570, is being amortized over the life of the loan. For the three months ended March 31, ~~2020.~~2021, $38,224 has been amortized. As of March 31, 2021, the fair value of the derivative liability was $416,513 and for the three months ended March 31, 2021, the Company recorded a gain of $44,215 from the change in fair value of derivative liability as other income in the consolidated statements of operations and comprehensive income (loss).

On January 7, 2021 (the “Issue Date”), the Company entered into a subscription agreement with an unaffiliated third party, whereby the Company issued for a purchase price of $100,000 in principal amount, a convertible promissory note. The note bears an interest rate of 8% per annum and matures on the earlier of (i) consummation of the Company listing its common shares on the NEO Stock Exchange or October 31, 2021.

Upon the consummation of a NEO listing, the total principal and accrued interest outstanding on the note will convert into shares of the Company’s common stock at a 25% discount to the prices of the common shares sold in the financing to be conducted in conjunction with the NEO listing. In the event that a NEO listing is not consummated on or before October 31, 2021, the note holder will have the option, in part or in full, to have the note repaid with interest, or convert the note into Company common stock at a 25% discount to the 30-day volume-weighted average price of the Common Shares on the most senior stock exchange in North American on which the common shares are trading prior to conversion. As of March 31, 2021, the Company had a principal balance of $100,000 and had accrued $1,734 in interest expense.

The Company determined that the embedded conversion feature of the convertible promissory note meets the definition of a beneficial conversion feature and a derivative liability which is accounted for separately. The Company measured the beneficial conversion feature’s intrinsic value on January 7, 2021 and determined that the embedded derivative was valued at $62,619 which was recorded as a debt discount and is being amortized over the life of the loan. For the three months ended March 31, 2021, $11,885 has been amortized. As of March 31, 2021, the fair value of the derivative liability was $45,461 and for the three months ended March 31, 2021, the Company recorded a gain of $17,158 from the change in fair value of derivative liability as other income in the consolidated statements of operations and comprehensive income (loss).

The table below provides a summary of the changes in fair value, including net transfers in and/or out of all financial liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2021:

The fair value of the derivative conversion features and warrant liabilities as of March 31, 2021 were calculated using a Monte-Carlo option model valued with the following assumptions:

A summary of the Company’s third-party debt during the three months ended March 31, ~~2020~~2021 and the year ended December 31, ~~2019~~2020 is presented below:

On ~~November 16, 2015,~~June 30, 2020, the Company entered into a ~~Loan Agreement with Panagiotis Drakopoulos, former Director and former Chief Executive Officer, pursuant to which~~settlement agreement on an existing loan facility agreement whereby the Company ~~borrowed €40,000 ($42,832)~~agreed to make certain payments to the creditor and the creditor will accept such payments as ~~a note payable~~full discharge of outstanding debt. In accordance with the settlement agreement, interest will accrue from ~~Mr. Drakopoulos. The note bears an interest~~June 30, 2020 until repayment in full at a rate of 6% per annum for the first year and ~~was~~5.25% per annum for the second year calculated on the balance outstanding from day to day during such period. Interest is due ~~and payable~~on the 10^th day of each calendar month. If any amount, principal or interest is unpaid on its due date interest shall accrue from the due date until the date of its payment until the date of its payment in full at the rate of 7.25% per annum. The Company will make quarterly payments of €125,000 beginning May 6, 2021 with a final payment of €2,200,000 on ~~November 15, 2016.~~May 6, 2022. The Company evaluated the settlement agreement for debt modification in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment as the 10% cash flow test was met. As a result, the $3,828,630 of principal and accrued interest was written off and the new debt was recorded at fair value as of June 30, 2020 in the amount of $3,033,990. As of December 31, ~~2019,~~2020, the Company ~~had an outstanding~~has accrued interest expense of $33,021 and the principal balance of ~~€13,000 ($14,595) and accrued interest~~the debt is $3,302,100, of ~~€4,166 ($4,677).~~which $2,843,475 is classified as Notes payable – long term portion on the consolidated balance sheet. As of March 31, ~~2020,~~2021, the Company ~~had an outstanding~~has accrued interest expense of $0 and the principal balance of ~~€13,000 ($14,321) and accrued interest~~the debt is $3,170,610, of ~~€4,362 ($4,805).~~which $2,583,460 is classified as Notes payable – long term portion on the condensed, consolidated balance sheet.

~~On August 4, 2016,~~The debt is subject to acceleration in an Event of Default (as defined in the ~~Company’s wholly owned subsidiary SkyPharm entered into a Loan Facility Agreement, guaranteed by Grigorios Siokas, with Synthesis Peer-To Peer-Income Fund (the “Loan Facility” the “Lender”)~~Notes). The Loan Facility initially provided SkyPharm with a credit facility of up to $1,292,769 (€1,225,141). Any advance under the Loan Facility accrues interest at a rate of 10% per annum and requires quarterly interest payments commencing on September 30, 2016. The amounts owed under the Loan Facility shall be repayable upon the earlier of (i) three months following the demand of the Lender; or (ii) August 31, 2018. No prepayment is permitted pursuant to the terms of the Loan Facility. The Synthesis Facility Agreement as amendedThis agreement is secured by a personal guaranty of Grigorios Siokas, which is secured by a pledge of 1,000,000 shares of common stock of the Company owned by Mr. Siokas.

On September 13, 2016, SkyPharm entered into a First Deed of Amendment with the Loan Facility increasing the maximum loan amount to $1,533,020 as a result of the Lender having advanced $240,251 (€227,629) to SkyPharm.

On March 23, 2017, SkyPharm entered into an Amended and Restated Loan Facility Agreement (the “A&R Loan Facility”), with the Loan Facility which increased the loan amount to an aggregate total of $2,664,960 (€2,216,736) as a result of the lender having advanced $174,000 (€164,898) in September 2016, $100,000 (€94,769) in October 2016, $250,000 (€236,922) in November 2016, $452,471 (€428,800) in December 2016, $155,516 (€129,360) in January 2017, $382,327 (€318,023) in July 2017 and $70,000 (€58,227) in December 2017. The A&R Loan Facility amends and restates certain provisions of the Loan Facility Agreement, dated as of August 4, 2016, by and among the same parties. Advances under the A&R Loan Facility continue to accrue interest at a rate of 10% per annum from the applicable date of each drawdown and require quarterly interest payments. The A&R Facility now permits prepayments at any time. The amounts owed under the A&R Loan Facility were repayable upon the earlier of (i) seventy-five days following the demand of the Lender; or (ii) August 31, 2018. The A&R Loan Facility is secured by a personal guaranty of Grigorios Siokas, which is secured by a pledge of 1,000,000 shares of common stock of the Company owned by Mr. Siokas (the “Pledged Shares”). The A&R Loan Facility was also amended to provide additional affirmative and negative covenants of Sky Pharm and the Guarantor during the term of loans remain outstanding, including, but not limited to, the consent of the Lender in connection with (i) the Company or any of its subsidiaries incurring any additional indebtedness; or (ii) in the event of any increase in the Company’s issued and outstanding shares of Common Stock, the Pledged Shares shall be increased to an amount equal to a minimum of ten percent (10%) of the issued and outstanding shares of the Company.

On April 18, 2018, the Company entered into an amendment with the Lender that was effective as of January 1, 2018, pursuant to which the maturity dates for all advances was extended to December 31, 2021. Additionally, the interest rate was amended such that the interest rate for all advances is 4% plus the 3-Month Libor rate. The Loan Facility also forgave €35,060 ($40,000) in fees related to the July 6, 2017 advance. As a result, the Company reduced the unamortized portion of debt discount that related to those fees and recorded a gain on debt settlement of €19,763 ($23,354).

As of December 31, 2019, the outstanding balance under the A&R Loan Facility was $3,078,442 (€2,741,999) and accrued interest expense of $609,607 (€542,983) has been recorded. As of March 31, 2020, the outstanding balance under this note was $3,078,442 (€2,794,519) and accrued interest expense of $651,611 (€591,514) has been recorded.

On March 16, 2017 and March 20, 2017, SkyPharm entered into loan agreements with the Synthesis Peer-To Peer-Income Fund (the “Bridge Loans”). The Bridge Loans provided to SkyPharm loans of €41,590 ($50,000) and €100,000 ($120,220), respectively, during the year ended December 31, 2017. The Bridge Loans accrue interest at a rate of 10% per annum and were repayable on April 16, 2017 and April 20, 2017, respectively, together with all other amounts then accrued and unpaid. On April 16, 2017, the maturity dates were amended for no additional consideration or change in terms and conditions. The maturity dates of both loans were amended, and they matured on May 16, 2017 and May 20, 2017, respectively. Pursuant to the April 18, 2018 agreement and effective January 1, 2018, the Company reached an agreement with Synthesis Peer-To-Peer Income Fund such that the March 20, 2017 loan would have a fixed USD payoff amount of $106,542. As a result of this agreement the Company recorded a gain on settlement of debt of €16,667 ($19,695) related to the reduction of the USD payoff amount and an additional gain on settlement of debt of €3,950 ($4,668) related to interest that had accrued on the original amount of the loan. The Company has accrued interest expense of an aggregate total of €24,608 ($27,627) for both loans and the outstanding balances of these loans was €45,809 ($50,000) and €83,333 ($106,542), respectively, as of December 31, 2019. The Company has accrued interest expense of an aggregate total of €27,187 ($29,950) for both loans and the outstanding balances of these loans was €45,389 ($50,000) and €896,715 ($106,542), respectively, as of March 31, 2020.

On May 5, 2017, SkyPharm entered into a loan agreement with Synthesis Peer-To-Peer Income Fund for €31,388 ($34,745). The loan accrues interest at a rate of 10% per annum and matured on September 30, 2017. The Company has accrued interest expense of €5,437 ($6,104) and the outstanding balance on this loan was €31,388 ($34,745) as of December 31, 2019. The Company has accrued interest expense of €5,972 ($6,579) and the outstanding balance on this loan was €31,541 ($34,745) as of March 31, 2020.

On April 18, 2018, the Company entered into an amendment pursuant to which the maturity dates for all of the above Bridge Loan advances were extended to December 31, 2021 for no additional consideration. Additionally, the interest rate was amended such that, effective January 1, 2018, the interest rate for all advances is 4% plus the 3-Month Libor rate.

On April 10, 2017, Decahedron entered into a Trade Finance Facility Agreement (the “Decahedron Facility”) with Synthesis Structured Commodity Trade Finance Limited (the “Lender”). The Decahedron Facility provides the following material terms:

On May 12, 2017, SkyPharm entered into a Trade Finance Facility Agreement (the “SkyPharm Facility”) with Synthesis Structured Commodity Trade Finance Limited (the “Lender”). The SkyPharm Facility provides the following material terms:

The Company obtained consents from Synthesis Peer-to-Peer Income Fund in connection with obtaining the Lender.

On November 16, 2017, SkyPharm signed an amended agreement with Synthesis Structured Commodity Trade Finance Limited that increased the maximum aggregate facility limit from €2,000,000 ($2,291,200) to €6,000,000 ($6,736,200). All other terms of the original agreement remain the same. The Company also obtained consents from Synthesis Peer-to-Peer Income Fund in connection with obtaining the November 2017 convertible debt financing.

On May 12, 2018, the Company borrowed an additional €270,000 ($247,117) in funds.

On May 16, 2018, SkyPharm S.A., as Commodity Buyer, entered into a Supplemental Deed of Amendment (the “Deed”) relating to a Trade Finance Facility dated May 12, 2017, as amended, with Synthesis Structured Commodity Trade Finance Limited (“Synthesis”), as Loan Receivables Originator. Under the Trade Finance Facility (the “TFF”) first entered into on May 12, 2017, as amended, there was a principal balance of €5,866,910 ($5,369,678) outstanding as of March 31, 2018. SkyPharm made a payment of €1,000,000 ($1,123,600) of interest and principal on May 31, 2018 under the terms and conditions of the Deed. Additionally, the maturity date for the facility has been amended such that, the full principal amount is to be repaid no later than May 31, 2021, subject to a repayment schedule to be agreed upon by SkyPharm and Synthesis Structure Commodity Trade Finance Limited. Synthesis Structure Commodity Trade Finance Limited may extend this final repayment date at its sole discretion.

The Deed is conditioned upon, among other things, execution and perfection of a Bulgarian Amended Pledge (“BAP”) having priority over the Bulgarian Pledge Accounts with Unicredit Bulbank AD; and the Approved Purchasers are to make all payments to SkyPharm directly to the BAP.

On May 16, 2018, SkyPharm and Synthesis also entered into an Account Merge Agreement (the “Pledge”) as a requirement under the above-described Deed. Under the Pledge, Synthesis is to receive a first ranking securities interest in SkyPharm’s outstanding receivables under the Bulgarian bank account.

On October 17, 2018, the Company entered into a further amended agreement with Synthesis whereby the current balance on the TFF as of October 1, 2018, which was €4,866,910 ($5,629,555) and related accrued interest of €453,094 ($524,094) would be split into two principal balances of Euro €2,000,000 and USD $4,000,000. Interest on the new balances commenced on October 1, 2018 at 6% per annum plus one-month Euribor, when it is positive, on the Euro balance and 6% per annum plus one-month Libor on the USD balance. The Company will repay the principal amounts of each balance beginning no later than August 31, 2018 in quarterly installments of €125,000 and US $150,000. The loan matures on August 31, 2021. The Company evaluated the amended agreement under ASC 470-50 and concluded that it did not meet the 10% cash flow test and recorded debt modification expense of $138,110.

As of December 31, 2019, the Company had a principal balance of €2,000,000 ($2,245,400) and $4,000,000 under the TFF and the Company had accrued $10,000 and $12,661, respectively in interest expense related to this agreement. As of March 31, 2020, the Company had principal balances of €2,000,000 ($~~2,203,200)~~2,446,000), of which $2,384,850 is classified as Notes payable – long term portion on the consolidated balance sheet, and $4,000,000 under the ~~TFF~~agreements and the Company had accrued ~~$9,918~~$402 and ~~$33,562~~$16,185 respectively, in interest expense related to ~~this agreement.~~these agreements. As of March 31, 2021, the Company had principal balances of €2,000,000 ($2,348,600), of which $2,231,170 is classified as Notes payable – long term portion on the consolidated balance sheet, and $4,000,000 under the agreements and the Company had accrued $9,495 and $14,800 respectively, in interest expense related to these agreements.

On November 16, 2015, the Company entered into a Loan Agreement with Panagiotis Drakopoulos, former Director and former Chief Executive Officer, pursuant to which the Company borrowed €40,000 ($42,832) as a note payable from Mr. Drakopoulos. The note bears an interest rate of 6% per annum and was due and payable in full on November 15, 2016. As of December 31, 2020, the Company had an outstanding principal balance of €8,000 ($9,784) and accrued interest of €4,785 ($5,852). As of March 31, 2021, the Company had an outstanding principal balance of €8,000 ($9,394) and accrued interest of €5,940 ($6,975).

In the years ending December 31, 2019 and 2020, the Company executed Senior Promissory Notes (the “Debt”) in an aggregate total of $3,010,000 to an unaffiliated third-party lender (the “Lender”). As of December 31, 2020, the Company had a principal balance of $3,010.00 on this Debt and the Company had accrued $527,604 in interest expense. As of February 5, 2021 The Company entered into an Amended and Restated Debt Exchange Agreement (the “Agreement”) with the “Lender that provided for the issuance by the Company of 781,819 shares of common stock (the “Exchange Shares”), at the rate of $3.85 per share, in exchange for an aggregate of $3,010,000 principal amount of existing loans made by the Lender to the Company. The market price at the time this Agreement was negotiated was $3.28 per share and the Company recorded a gain on debt extinguishment of $445,636.

All accrued and unpaid interest, $563,613 as of March 31, 2021, as well as any unpaid fees, shall be paid in three (3) equal monthly installments following the closing of a planned Canadian public offering. Pursuant to this Agreement, Grigorios Siokas, the Company’s Chief Executive Officer and principal shareholder, will be released from all personal guarantees on the Debt.

On May 18, 2020, the Company executed a Senior Promissory Note (the “May 18 Note”) in the principal amount of $2,000,000 payable to an unaffiliated third-party lender. The May 18 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The May 18 Note matured on December 31, 2020. The note is not in default and the Company is currently in negotiations with the lender to extend the maturity date.

The May 18 Note is subject to acceleration in an Event of Default. Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the May 18 Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. As of March 31, 2021 and December 31, 2020, the Company had a principal balance of $2,000,000 on this note.

On July 3, 2020, the Company executed a Senior Promissory Note (the “July 3 Note”) in the principal amount of $5,000,000 payable to an unaffiliated third-party lender. The July 3 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The July 3 Note matures on June 30, 2022 unless in default.

The July 3 Note is subject to acceleration in an Event of Default (as defined). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the July 3 Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection.

As of March 31, 2021 and December 31, 2020, the Company had a principal balance of $5,000,000 on this note, which is classified as long-term on the consolidated balance sheet.

As of March 31, 2021 and December 31, 2020, the Company has accrued an aggregate total of $459,368 and $146,685 in accrued interest expense related to these loans.

On August 4, 2020, the Company executed a Senior Promissory Note (the “August 4 Note”) in the principal amount of $3,000,000 payable to an unaffiliated third-party lender. The August 4 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The August 4 Note matured on December 31, 2020 unless in default.

The August 4 Note is subject to acceleration in an Event of Default (as defined). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the August 4 Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection.

On October 29, 2020, the Company entered into a debt exchange agreement with the lender whereby the Company issued 259,741 shares of common stock at the rate of $3.85 per share in exchange for an aggregate of $1,000,000 principal amount of the existing loan. The fair market value of the Company’s common stock on the date of exchange was $3.11 per share and as such, the Company recorded a gain of $192,205. Interest will continue to accrue on the remaining debt and the converted amount until December 31, 2020. As of December 31, 2020, the Company had a principal balance of $2,000,000 on this note and prepaid interest of $8,514. As of March 31, 2021, the Company had a principal balance of $2,000,000 on this note and $97,282 in accrued interest expense. The note is not in default and the Company is in negotiations with the lender to extend the maturity date.

On November 19, 2020, the Company entered into an agreement with a third-party lender in the principal amount of €500,000 ($611,500). The note matures on November 18, 2025 and bears an annual interest rate, based on a 360-day year, of 3.3% plus .6% plus 6-month Euribor when Euribor is positive. Pursuant to the terms of the agreement, there is a six-month grievance from the first deposit date, which was November 19, 2020, for both interest accrual and principal repayment. The principal is to be repaid in 18 quarterly installments of €27,000 with the first payment due 9 months from the first deposit. As of December 31, 2020, the Company had no accrued interest and a principal balance of €500,000 ($611,500), of which $543,557 is classified as Notes payable – long term portion on the consolidated balance sheet. As of March 31, 2021, the Company had no accrued interest and a principal balance of €500,000 ($587,150), of which $489,294 is classified as Notes payable – long term portion on the consolidated balance sheet.

On May 12, 2020, the Company was granted and on May 22, 2020 the Company received a €300,000 ($337,110) loan from the Greek government. The loan will be repaid in 40 equal monthly instalments beginning on January 1, 2022 and bears an interest rate of 0.94% per annum. As a condition to the loan, the company is required to retain the same number of employees until October 31, 2020. The balance as of March 31, 2021 was $352,290.

On June 24, 2020, the Company received a loan £50,000 ($61,845) from the Greek government. The loan has a six-year maturity and bears interest at a rate of 2.5% per annum beginning 12-months after the initial disbursement. The Company may prepay this loan without penalty at any time. The balance as of March 31, 2021 was $68,975.

As discussed in Note 43 above, the Company entered into a Distribution and Equity Acquisition Agreement with Marathon. The Company was appointed the exclusive distributor of the Products (as defined) initially throughout Europe and on a non-exclusive basis wherever else lawfully permitted. As consideration for its services, Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in Common Shares of the Company if it fails to meet certain performance milestones. The Company is entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000.

As discussed in Note 4,3, the Company attributed no value to the shares received in Marathon pursuant to (a) above. In relation to the CAD $2 million cash received noted in (b) above, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million). If settlement were to occur on December 31, 2019, the Company would be required to issue ~~796,155~~285,606 common shares to settle its debt obligation. The Company could be obligated to potentially issue an unlimited number of common shares to settle its Share-settled debt obligation. If such events were to occur, the Company would be required to increase its authorized share capital and since increasing the authorized share capital is within the control of the Company, as our CEO controls greater than 50% of the outstanding common stock of the Company, the original classification of equity-classified financial ~~instruments issued by the Company were not affected.~~

On April 1 and 3, 2019, the Company executed Senior Promissory Notes (the “Notes”) each in the principal amount of $250,000 payable to an unaffiliated third-party lender. The Notes bear interest at the rate of fifteen (15%) percent per annum, paid quarterly in arrears. The Notes matured on April 1 and 3, 2020 unless prepaid or in default. The Company is currently in discussions with the lender to extend the maturity date and is not in default. The Company may prepay the Notes within the first six (6) months by payment of unpaid interest for the first six (6) months interest and after six (6) months, with a (2%) percent ($5,000) premium on each note.

The Notes are subject to acceleration in an Event of Default (as defined in the Notes). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the Notes. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. As of December 31, 2019, the Company had a principal balance $250,000 and $250,000 on these notes and the Company had accrued $9,452 and $28,098, respectively, in interest expense. As of March 31, 2020, the Company had a principal balance $250,000 and $250,000 on these notes and the Company had accrued $18,801 and $37,447 respectively, in interest expense.

On April 9, 2019, the Company executed a Senior Promissory Note (the “Note”) in the principal amount of $250,000 payable to an unaffiliated third-party lender who had previously loaned the Company $500,000. The Note bears interest at the rate of fifteen (15%) percent per annum, paid quarterly in arrears. The Note matured on April 9, 2020, unless prepaid or in default. The Company is currently in discussions with the lender to extend the maturity date and is not in default. The Company may prepay the Note within the first six (6) months by payment of unpaid interest for the first six (6) months and after six (6) months, with a two (2%) percent ($5,000) premium.

The Note is subject to acceleration in an Event of Default (as defined in the Note). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. As of December 31, 2019, the Company had a principal balance $250,000 on this Note and the Company had accrued $27,431 in interest expense. As of March 31, 2020, the Company had a principal balance $250,000 on this Note and the Company had accrued $36,780 in interest expense.

On July 24, 2019, the Company executed a Senior Promissory Note (the “July Note”) in the principal amount of $750,000 payable to an unaffiliated third-party lender who had previously loaned the Company $750,000. The funds represented by the July Note were advanced between July 19 and 24, 2019. The July Note bears interest at the rate of fifteen (15%) percent per annum, paid quarterly in arrears. The July Note matures on July 24, 2020, unless prepaid or in default. The Company may prepay the July Note within the first six (6) months by payment of unpaid interest for the first six (6) months and, after six (6) months, with a two (2%) percent ($15,000) premium.

The July Note is subject to acceleration in an Event of Default. Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the July Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. As of December 31, 2019, the Company had a principal balance $750,000 on this note and the Company had accrued $49,625 in interest expense. As of March 31, 2020, the Company had a principal balance $750,000 on this note and the Company had accrued $77,673 in interest expense.

On August 1, 2019, the Company executed a Senior Promissory Note (the “August Note”) in the principal amount of $500,000 payable to an unaffiliated third-party lender who had previously loaned the Company $1,500,000. The August Note bears interest at the rate of fifteen (15%) percent per annum, paid quarterly in arrears. The August Note matures on August 1, 2020, unless prepaid or in default. The Company may prepay the August Note within the first six (6) months by payment of unpaid interest for the first six (6) months and, after six (6) months, with a two (2%) percent ($10,000) premium.

The August Note is subject to acceleration in an Event of Default. Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the August Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. As of December 31, 2019, the Company had a principal balance $500,000 on this note and the Company had accrued $31,438 in interest expense. As of March 31, 2020, the Company had a principal balance $500,000 on this note and the Company had accrued $50,137 in interest expense.

On October 23, 2019, the Company executed a Senior Promissory Note (the “October Note”) in the principal amount of $250,000 payable to an unaffiliated third-party lender who had previously loaned the Company $2,000,000. The October Note bears interest at the rate of fifteen (15%) percent per annum, paid quarterly in arrears. The October Note matures on October 23, 2020, unless prepaid or in default. The Company may prepay the October Note within the first six (6) months by payment of unpaid interest for the first six (6) months and, after six (6) months, with a two (2%) percent ($5,000) premium.

The October Note is subject to acceleration in an Event of Default. Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the October Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. As of December 31, 2019, the Company had a principal balance $250,000 on this note and the Company had accrued $7,705 in interest expense. As of March 31, 2020, the Company had a principal balance $250,000 on this note and the Company had accrued $17,054 in interest expense.

On December 6, 2019, the Company executed a Senior Promissory Note (the “December Note”) in the principal amount of $250,000 payable to an unaffiliated third-party lender who had previously loaned the Company $2,250,000. The December Note bears interest at the rate of fifteen (5%) percent per annum, paid quarterly in arrears. The December Note matured on March 31, 2020, unless prepaid or in default. The Company is currently in discussions with the lender to extend the maturity date and is not in default. The Company may prepay the December Note after six (6) months, with a two (2%) percent ($5,000) premium.

The December Note is subject to acceleration in an Event of Default. Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the December Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. As of December 31, 2019, the Company had a principal balance $250,000 on this note and the Company had accrued $890 in interest expense. As of March 31, 2020, the Company had a principal balance $250,000 on this note and the Company had accrued $4,007 in interest expense.

On January 27, 2020, the Company executed a Senior Promissory Note (the “January Note”) in the principal amount of $250,000 payable to an unaffiliated third-party lender who had previously loaned the Company $2,500,000. The January Note bears interest at the rate of five (5%) percent per annum, paid quarterly in arrears. The January Note matures on May 15, 2020 unless in default. The Company may prepay the January Note within the first six (6) months by payment of unpaid interest for the first six (6) months and, after six (6) months, with a two (2%) percent ($5,000) premium.

The January Note is subject to acceleration in an Event of Default (as defined). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the January Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. As of March 31, 2020, the Company had a principal balance of $250,000 on this note and the Company had accrued $2,226 in interest expense.

On February 25, 2020, the Company executed a Senior Promissory Note (the “February Note”) in the principal amount of $1,000,000 payable to an unaffiliated third-party lender. The February Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The February Note matures on April 30, 2020 unless in default.

The February Note is subject to acceleration in an Event of Default (as defined). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the February Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. As of March 31, 2020, the Company had a principal balance of $1,000,000 on this note and the Company had accrued $17,754 in interest expense.

On February 27, 2020 and March 23,2020, the Company executed two Senior Promissory Notes (the “Quarter-1 Notes”) in the principal amounts of $25,000 and $35,000, respectively, payable to an unaffiliated third-party lender who had previously loaned the Company $2,750,000. The Quarter-1 Notes bear interest at the rate of five (5%) percent per annum, paid quarterly in arrear and mature on December 31, 2020 unless in default. The Company may prepay the Quarter-1 Notes within the first six (6) months by payment of unpaid interest for the first six (6) months and, after six (6) months, with a two (2%) percent ($500 and $700, respectively) premium.

The Quarter-1 Notes are subject to acceleration in an Event of Default (as defined). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the Quarter-1 Notes. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. As of March 31, 2020, the Company had a principal balance of $25,000 and $35,000, respectively, on these notes and the Company had accrued an aggregate of $159 in interest expense.

The Company has various lease agreements with terms up to 10 years, comprising leases of office space. Some leases include options to purchase, terminate or extend for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised.

The assets and liabilities from operating and finance leases are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company’s secured incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet.

The Company’s operating leases do not provide an implicit rate that can readily be determined. Therefore, we use a discount rate based on our incremental borrowing rate, which is determined using the interest rate of our long-term debt as of January 1, 2019.

The Company’s weighted-average remaining lease term relating to its operating leases is ~~6.82~~4.84 years, with a weighted-average discount rate of 6.74%.

The Company incurred lease expense for its operating leases of ~~$53,576~~$64,577 and ~~$52,508~~$53,576 which was included in “General and administrative expenses,” for the three months ended March 31, ~~2020~~2021 and ~~2019,~~2020, respectively.

~~The Company had operating cash flows used in operating leases of $53,600 for the three months ended~~

The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of March 31, ~~2020.~~2021.

The Company’s weighted-average remaining lease term relating to its finance leases is ~~2.69~~2.68 years, with a weighted-average discount rate of ~~6.71%~~6.74%.

The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s finance leases as of March 31, ~~2020.~~2021.

The Company had operating cash flows used in finances leases of $4,453 and $2,301 for the three months ended March 31, ~~2020. The Company had financing cash flows used in finances leases of $19,886 for the three months ended March 31, 2020.~~2021 and 2020, respectively.

The Company incurred interest expense on its finance leases of ~~$2,301~~$4,453 which was included in “Interest expense,” for the three months ended March 31, ~~2020.~~2021. The Company incurred amortization expense on its finance leases of ~~$38,248~~$26,755 which was included in “Depreciation and amortization expense,” for the three months ended March 31, ~~2020.~~

From time to time, the Company may be involved in litigation relating to claims arising out of the Company’s operations in the normal course of business. As of March 31, ~~2020,~~2021, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company’s operations.

On October 1, 2016, the Company entered into an Intellectual Property Sale Agreement with Anastasios Tsekas and Olga Parthenea Georgatsou (the “IPSA”) for the purchase of certain intellectual property rights relating to proprietary pharmaceutical formulas and any related technical information arising or related thereto (the “Intellectual Property”). The IPSA provides that the sellers shall be entitled to an aggregate of 200,000 shares of common stock of the Company, none of which have been issued to date, and issuable as follows in equal parts to each seller:

The Company has agreed to pay Anastasios Tsekas €1,500 per month until the first issuance of the shares referenced above. The Company has also agreed that in the event the Company disposes of the Intellectual Property prior to the periods referenced above, the sellers shall be entitled to the issuance of all the shares referenced above. The Company has not received yet the formula from Tseka as of today and therefore the Company was not able to proceed with any of the above cases or any preclinical trials phases.

On August 8, 2017, the Company entered into an agreement with a third-party placement agent (the “Agent”) who will serve as the Company’s exclusive placement agent or sole book running manager with respect to any offerings of equity or equity-linked securities as well as any debt offering with the two organizations named in the agreement (the “Offering”) for a period of 120 days. In the event that an Offering is agreed upon by the Agent and the Company, the Company shall provide payment as follows: (1) a cash commission of 6% of the total gross proceeds for two named investors (2) a cash commission of 4% of total gross proceeds from five named investors and (3) excluding the five named investors in “(2)” a cash commission equal to 8% of the total gross proceeds from the Offering and the issuance to the Agent or its designees of warrants covering 8% of the shares of common stock issued or issuable by the Company in the Offering. Additionally, the Agent will receive a cash fee of 8% payable within 5 business days, but only in the event of, the receipt by the Company of any cash proceeds from the exercise of any warrants with an expiration equal to or less than 24 months sold in the Offering. In connection with the Company’s November 16, 2017 Note offering, the Agent received a cash commission of $240,000, equal to eight (8%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase eight (8%) percent of the shares of common stock issued or issuable in the offering (excluding shares of common stock issuable upon exercise of any warrants issued to investors, or 53,600 shares); however, will receive eight (8%) percent of any cash proceeds received from the exercise of any warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The warrants are exercisable six (6) months after the date of issuance, or as of May 16, 2018.

In connection with the Company’s September 4, 2018 Note offering, the Agent received a cash commission for this transaction of $140,000, equal to seven (7%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase seven (7%) percent of the shares of common stock issued or issuable in this offering (excluding shares of common stock issuable upon exercise of any warrants issued to investors, or 26,056 shares); however, will receive seven (7%) percent of any cash proceeds received from the exercise of any warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The warrants are exercisable six (6) months after the date of issuance, or March 4, 2019.

On April 18, 2018, SkyPharm S.A. entered into a ten-year Advisory Agreement with Synthesis Management Limited (the “Advisor”). The Advisor was retained to assist SkyPharm to secure corporate finance capital. The Advisor shall be paid €104,000 per year during the ten-year term.

As of March 31, ~~2020,~~2021, there were ~~74,000~~37,000 options outstanding and ~~74,000~~37,000 options exercisable with expiration dates ~~commencing October 2020 and continuing through~~of January 2022.

A summary of the Company’s option activity during the three months ended March 31, ~~2020~~2021 is presented below:

As of March 31, ~~2020,~~2021, there were 1,164,673 warrants outstanding and 1,164,673 warrants exercisable with expiration dates from May 2023 through March 2024.

A summary of the Company’s warrant activity during the three months ended March 31, ~~2020~~2021 is presented below:

ASC 606-10-50-5 requires that entities disclose disaggregated revenue information in categories (such as type of good or service, geography, market, type of contract, etc.). ASC 606-10-55-89 explains that the extent to which an entity’s revenue is disaggregated depends on the facts and circumstances that pertain to the entity’s contracts with customers and that some entities may need to use more than one type of category to meet the objective for disaggregating revenue.

The Company disaggregates revenue by country to depict the nature and economic characteristics affecting revenue. The following table presents our revenue disaggregated by country for the three months ended:

Country	March 31, 2020		March 31, 2019		March 31, 2021		March 31, 2020
Belgium	$	-	$	-
Croatia		-		5,395
Cyprus					$	14,723	$	-
Denmark		-		57,657		54,686		-
France		1,091		42,061		-		1,091
Georgia		-		-
Germany		667,302		2,076,814		13,613		667,302
Greece		10,689,681		5,456,573		11,453,496		10,689,681
Hungary		36,140		49,912		-		36,140
Indonesia		-		-
Iraq		-		-
Ireland		35,113		132,417		-		35,113
Italy		6,041		73,437		15,727		6,041
Jordan		9,417		20,432		-		9,417
Netherlands		41,983		337,683		-		41,983
Poland		33,455		138,270		-		33,455
Turkey		28,398		24,695		-		28,398
UK		384,627		1,267,995		66,831		384,627
Total	$	11,933,248	$	9,683,341	$	11,619,076	$	11,933,248

On ~~April 23, 2020,~~or about July 25, 2019, Mark Rubenstein, individually and as a shareholder of the Company, ~~executed a Senior Promissory Note (the “April Note”~~brought the action styled Rubenstein v. Siokas, et al., Case No. 1:19-cv-06976-KPF (S.D.N.Y.) inagainst Grigorios Siokas for recovery of alleged profits earned under Section 16(b) of the ~~principal amount~~Securities Exchange Act of ~~$200,000 payable to an unaffiliated third-party lender who had previously loaned~~1934. Although recovery was sought only from Mr. Siokas, the Company ~~$2,810,000. The April Note bears interest at~~was also named as a nominal defendant. Both the ~~rate of five (5%) percent per annum, paid quarterly in arrears. The April Note matures on December 31,~~Company and Mr. Siokas vigorously defended the lawsuit. On or about September, 18, 2020, unless in default. The Company may prepay the April Note within the first six (6) months by payment of unpaid interest for the first six (6) months and, after six (6) months, with a two (2%) percent ($4,000) premium.

~~The April Note is subject to acceleration~~ in an ~~Event~~effort to avoid the uncertainty of ~~Default (as defined). Grigorios~~litigation and further legal expense, Mr. Siokas agreed to settle the ~~Company’s CEO, personally guaranteed repayment~~lawsuit by agreeing to reimburse the Company a total of six hundred thousand ($600,000) dollars, payable as a combination of: (1) Mr. Siokas reimbursing the Company for Plaintiff’s attorneys’ fees, in an amount subsequently determined by the Court to be $120,000 plus $4,137 of litigation costs to be paid in cash, and (2) Mr. Siokas relieving the Company of certain debt owed to him. The terms of the ~~April Note. The guaranty is unconditional~~settlement between Mr. Siokas and ~~irrevocable~~the Company are set forth in a Debt Exchange Agreement dated May 10, 2021 filed as an exhibit to this Form 10-Q. Mr. Siokas and ~~constitutes a guaranty of performance and of payment when due, and not just of collection.~~the Company strongly opposed Plaintiff’s motion for attorneys’ fees.

On May 5, 2020, the Company executed a Senior Promissory Note (the “May 5 Note”) in the principal amount of $2,000,000 payable to an unaffiliated third-party lender. The May 5 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The May 5 Note matures on December 31, 2020 unless in default.

The May 5 Note is subject to acceleration in an Event of Default (as defined). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the May 5 Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection.

On May 8, 2020, the Company executed a Senior Promissory Note (the “May 8 Note”) in the principal amount of $2,000,000 payable to an unaffiliated third-party lender. The May 8 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The May 8 Note matures on June 8, 2020 unless in default.

The May 8 Note is subject to acceleration in an Event of Default (as defined). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the May 8 Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection.

The following discussion should be read in conjunction with our interim Condensed Consolidated Financial Statements and the related notes and other financial information appearing elsewhere in this report as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Form 10-K for the year ended December 31, 2020 (“Form 10-K”) and this Quarterly Report on Form 10-Q for the quarter ended March 31, 2021.

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions.

We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements, ~~contained in the Private Securities Litigation Reform Act of 1995~~ and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.

Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Cosmos Holdings, Inc. was formed as a Nevada incorporation on July 07, 2009, under the name of Prime Estates & Developments Inc. Effective September 27, 2013, ~~the Company closed a reverse take-over transaction pursuant to which it~~we acquired 100% ownership of Amplerissimo Ltd., a private company whose principal activities ~~are the trading of products,~~included providing ~~representation, and provision of~~ consulting services to various industries. Pursuant to a Share Exchange Agreement between the Company and Amplerissimo Ltd. (“Amplerissimo”), a company incorporated in Cyprus, we acquired 100% of Amplerissimo’s issued and outstanding common stock. On November 14, 2013, we changed our name to Cosmos Holdings, Inc. and changed our focus and business strategy to the healthcare and pharmaceutical industry. The Company, through Amplerissimo Ltd, formed SkyPharm S.A. on August 01, 2014, a Greek Corporation which focuses on pharmaceutical products and is engaged in the trading of branded and generic pharmaceutical products and medicines across the European Union member states. On February 10, 2017, we acquired 100% ownership of Decahedron Ltd., a United Kingdom company whose principal activity is the same as the business of SkyPharm S.A. In addition, on December 19, 2018, the Company acquired 100% ownership of Cosmofarm Ltd, a Greek company which is a pharmaceutical wholesaler and networks with over 1,500 pharmacies.

The Company operates in the import/export and wholesale distribution of branded pharmaceutical products, generic pharmaceuticals, over the counter (OTC) products and a variety of nutraceuticals, including its own branded label.

We conduct wholesale import and export of branded pharmaceutical products throughout Europe by our subsidiaries, SkyPharm S.A. and Decahedron Ltd. We source licensed pharmaceuticals from wholesalers at a lower cost, primarily in Greece and the U.K. and sell to other European wholesalers.

We conduct direct distribution and sales of pharmaceuticals, medical devices, generic pharmaceuticals and OTC products through our subsidiary, Cosmofarm S.A. Our distribution network exceeds over 1,500 pharmacies in Greece. We have created an upgraded and high-end distribution center in Greece due to our Robotic systems and integrated automations (ROWA robotics).

We have created and developed our own proprietary branded nutraceutical products, named “Sky Premium Life” which was launched in 2018. Our portfolio includes at least 67 product codes including vitamins, minerals and other herbal extracts. We expect to reach the number of 71 product codes by the end of 2020. Our Nutraceutical products are manufactured exclusively by Doc Pharma S.A., a related party of the Company.

We focus on nutraceutical products because we foresee it as a relatively under-penetrated market throughout Europe with potential of high growth opportunities due to its ~~subsidiaries,~~large market size and margin contribution as the demand for nutraceutical products is increasing globally.

We are engaged in the distribution and sale of generic pharmaceutical products throughout Europe. Through our related company, Doc Pharma, we have the distribution rights to over 47 generic licenses of fast-moving product codes.

Our subsidiaries’ licenses help us establish and enhance our market share. SkyPharm received its Authorization for the Wholesale Distribution of Medical Products for humans use on July 22, 2015, from the Hellenic Republic National Organization for Medicines in accordance with Law 1316/1983, and the inspection by the National Organization for Medicines dated July 16, 2015 in accordance with the Guidelines 2013/C31/01. The license is valid for five years and expires on July 22, 2020. Pursuant to the EU directive of (2013/C 343/01), the Company is subject to fulfill the Guidelines of the Good Distribution Practices of medical products for human use. The Company submitted its application for renewal one month before the license expiration to the Hellenic Republic National Organization, but according to the EMA (eudragmdp.ema.europa.eu/inspections/view/wda/WDAHomePage.xhtml): “Due to the restrictions caused by COVID-19, the period of validity of MIA’s, WDA’s, GMP and GDP certificates is automatically extended until the end of 2021. On-site inspections will resume as soon as there is a consensus that the period of the public health crisis has passed. The clarifying remark section of individual MIA’s, WDA’s, GMP and GDP certificates will indicate any exceptions. Competent authorities reserve the right to inspect a manufacturing site should the need arise.” Therefore, the Company is eligible to continue its operations until the end of 2021.

Our subsidiary, Decahedron, was granted the license for the wholesale of medicinal products for human use in February 2021 pursuant to the regulation of 18 of The Human Medicines Regulations 2012 (SI 2012/1916). It fulfills the guidelines of the Wholesale Distribution Authorisation (Human). Finally, our subsidiary, Cosmofarm S.A., was granted the license for the wholesale of pharmaceutical products for human use on February 2019 pursuant to the EU directive of (2013/C 343/01). It fulfils the Guidelines of the Good Distribution Practices of medical products for human use. All licenses were granted based on inspections and are valid unless current inspections occur which will revise their status.

The Company uses a differentiated operating ~~within the pharmaceutical industry~~model based on a lean, nimble and ~~in order to compete successfully the healthcare industry, must demonstrate that its products offer medical benefits~~decentralized structure, an emphasis on low-risk license acquisition, as well as ~~cost advantages. Currently, most~~research & development and our ability to be better owners of pharmaceutical assets than others. This operating model and the ~~products that~~execution of our Corporate Strategy are enabling the Company ~~is trading, compete with other products already on the market in the same therapeutic category,~~to achieve sustainable growth and ~~are subject to potential competition from new products that competitors may introduce in the future.~~create shareholder value.

We are currently focusing our existing operations on expanding the business of our subsidiaries. Our operating model and the execution of our corporate strategy are designed to enable the Company to achieve sustainable growth and create shareholder value.

Supply chain disruption is a growing concern for the ~~Hellenic Ministry~~European pharmaceutical industry as it increasingly looks to cut costs by relying on ‘emerging markets’, where standards can be lower in terms of ~~Health~~compliance, ethics and health and safety.

Hikes in the price of medicine and their impact on the sustainability of the healthcare systems are garnering more and more ~~specifically~~attention. European regulators are willing to play their part in safeguarding continued access to safe and effective medicines. Regulators can speed up the ~~National Organization for Medicines granted~~approval of generics and biosimilars to boost competition and drive down prices.

Cuts in healthcare spending keep occurring since the license for the wholesale of pharmaceutical products for human use to SkyPharm. The license is valid for a period of five years and pursuant to the EU directive of (2013/C 343/01) the Company is subject to fulfill the Guidelinesfinancial crises of the ~~Good Distribution Practices~~late of ~~medical products for human use. The Company~~2000s. Europe’s slow recovery has ~~already incorporated the methodologies, procedures, processes~~been uneven, with austerity and resources in order to be in accordance with the guidelines of the Good Distribution Practices. In 2016, the Company leased and equipped additional office space for our subsidiary SkyPharm in Thessaloniki, Greece in order to facilitate its growing business activity. The warehouse was already equipped with the proper shelves, working tables, medicine, cold fridge and barcode machines in compliance with all regulations.

On May 20, 2016, the Company entered into a Non-Binding Memorandum of Understanding with Doc.Pharma S.A. to purchase the company for a combination of cash and stock to be agreed upon. Doc Pharma S.A is considered a related party to the Company due to the fact that the CEO of Doc Pharma is the wife of Grigorios Siokas, the Company’s CEO and principal shareholder, who also served as a principal of Doc Pharma SAeconomic uncertainty, especially in the past. Doc Pharma is a pharmaceutical manufacturer with production facilities in Athens, Greece, certified under Good Manufacturer Practices (GMP). The company owns numerous licenses of generic medicines and uses its own network of pharmaceutical sales representatives to communicate its products with doctors. The company also trades prototype medicines and food supplements. Closing of the transaction is subject to execution of definitive exchange agreements, a full audit of Doc Pharma, satisfactory completion of due diligence of Doc Pharma, tax and legal consideration and other customary closing conditions. The Memorandum of Understanding expired on December 31, 2016, and has not been formally renewed or extended, however is being pursued.

On November 17, 2016, Cosmos Holdings Inc. entered into a Stock Purchase Agreement (the “Decahedron SPA”) with Decahedron Ltd. (“Decahedron”) and the shareholders of Decahedron. The Company consummated this transaction on February 10, 2017. The terms of the Decahedron SPA provided that the Company would acquire all of the issued and outstanding shares of Decahedron. In exchange for the shares of Decahedron, the Company will issue to the Decahedron shareholders an aggregate amount of 170,000 shares of the Company’s common stock.

On August 25, 2017, we received shareholder and board approval for a reverse stock split of our common stock on the basis of issuing one (1) share of common stock in exchange for each ten (10) shares of common stock issued and outstanding. On November 21, 2017, the reverse stock split was made affective by FINRA. On November 21, 2017, the Company effected a one-for-ten (1:10) reverse stock split whereby the Company decreased, by a ratio of one-for-ten (1:10) the number of issued and outstanding shares of Common Stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, and warrants including all share and per-share data, for all amounts and periods presented in the consolidated financial statements. All share and per share data in this report gave retroactive effect to the reverse stock split unless otherwise noted.

As of October 3, 2017, the Company, entered into a Research & Development agreement with Doc Pharma. The agreement outlines the development and contract manufacturing of Cosmos Holdings’ complete line of nutraceutical products. Under the agreement, Doc Pharma S.A. will provide its services to research, develop formulation, complete product registration, design product packaging, and provide market-ready products. Sales of food supplements by the Company commenced in the third quarter of 2018. Sales of the Company’s own line of nutraceuticals, ~~SkyPremium Life~~~~, commenced in the fourth quarter of 2018.~~

On November 15, 2017, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain institutional investors (the “Buyers”) with which it had no prior relationship, pursuant to which the Company issued for a purchase price of $3,000,000, $3,350,000 in aggregate principal amount of Senior Convertible Notes (the “Notes”) to the Buyers, convertible into 670,000 shares of the Company’s common stock, par value $.001 per share (the “Common Stock”) at $5.00 per share and warrants to purchase an aggregate of 536,000 shares of Common Stock exercisable (the “Warrants”) at $7.50 per share.

On September 4, 2018, the Company entered into a Securities Purchase Agreement (the “SPA”) and completed the financing with two institutional investors who had previously purchased $3,350,000 principal amount of senior convertible notes in November 2017 (the “November Notes”)EU’s poorer member states, such as amended in February 2018 and September 2018. The Company issued, for a $2,000,000 purchase price, $2,233,333 in aggregate principal amount of Senior Convertible Notes (the “Notes”) convertible into 372,223 shares of Common Stock at $6.00 per share and five-year Warrants to purchase an aggregate of 357,334 shares of common stock exercisable at $7.50 per share. The Company received net proceeds of $1,845,000 after deduction of offering costs.

On September 30, 2018, the Company entered into a Share Purchase Agreement (“SPA”) with Abbydale Management Limited, an unaffiliated third party incorporated in Belize. The Company sold one hundred (100%) percent of the issued share capital of its subsidiary, Amplerissimo Ltd., a limited liability company organized under the laws of Cypress, to the purchaser for a purchase price of €5,000. Amplerissimo had previously transferred one hundred (100%) percent of the capital stock of Sky Pharm SA to the Company. The information technology business of Amplerissimo is not a priority of the Company and the Company decided to not pursue such business.

~~On December 19, 2018, the Company completed the purchase of all of the capital stock of Cosmofarm Ltd., a pharmaceutical wholesaler based in Athens,~~ Greece. The principal of the selling shareholder is Panagiotis Kozaris, who remained with Cosmofarm as a director and chief operating officer once it became a wholly-owned subsidiary of the Company. Grigorios Siokas, the Company’s CEO, became the new CEO of Cosmofarm. Mr. Kozaris had no prior relationship to the Company other than as an independent shareholder. The purchase price payable is €200,000 evidenced by a promissory note. Closing of the acquisition was subject to satisfactory completion of due diligence, delivery of audited and interim financial statements of Cosmofarm subject to being audited by PCAOB auditors, no material adverse change in the business or financial condition of Cosmofarm, all necessary consents and approvals to complete the acquisition have been obtained and other customary closing conditions.

The World Health Organization (WHO) declared the coronavirus outbreak a pandemic on ~~January 30,~~March 11, 2020. Since the outbreak in China in December 2019, COVID-19 has expanded its impact to Europe, where all of our operations reside as well as our employees, suppliers and customers. To date, our operations have been adversely affected by the following ~~adverse~~Covid-19 risks:

Management believes that there could be a positive long-term outcome from Covid-19, which could result in an increase in sales of OTC branded products, ~~food supplements,~~nutraceuticals, antibacterial products, gloves, oximeters, thermometers and medical masks. However, there is no guarantee of such results. Therefore, we will increase R&D as we are aiming to innovate and create new products in order to help combat against ~~COVID-19.~~Covid-19. We have adapted our strategy in response to ~~COVID-19~~Covid-19 and will continue to do so, since we are expecting the impact of ~~COVID-19~~Covid-19 to continue for the next 18-24 months.

What Effect Will ~~COVID-19~~Covid-19 Have on the Company’s Disclosure Controls

Management does not believe COVID-19 will have a significant effect on our disclosure controls as there have been no changes to date. Our operations have continued at a normal pace, at least 90% of our staff continue to work on site and those staff who are working remotely have no impact on our disclosure controls.

~~Three Months~~Three-Months Ended March 31, ~~2020 versus March 31, 2019~~2021

~~For~~The Company had revenue of $11,619,076 and $11,933,248 (a decrease of 2.63%) for the three months ended March 31, 2021 and 2020, respectively. This decrease is mainly due to the decrease in demand for full line wholesale products. Our subsidiary, Skypharm, was focused this quarter on the sales of “Sky Premium Life” products. The Company had a net loss of $2,173,903 on revenue of $11,619,076 versus a net loss of $483,310 on revenue of $11,933,248 ~~versus net loss of $217,173 on revenue of $9,683,341~~ for the three months ended March 31, ~~2019.~~2021 and 2020, respectively.

~~For the three months ended March 31, 2020, we~~The Company had ~~direct~~ costs ~~of revenue of $10,740,077 associated with cost~~ of goods sold of $10,617,741 versus ~~$9,057,179~~$10,740,077 for the three months ended March 31, ~~2019.~~

~~Revenue as~~2021 and 2020, respectively. This decrease is equivalent to the decrease of ~~March 31, 2020, was increased by 23.23%~~revenue due to a decrease in comparison to revenues in the period ended March 31, 2019. This increase is mainly because of the organic growth attributed to our subsidiary, Cosmofarm, which continued the expansion of point sales even more aggressively during the current year. In addition, there was an increased demand ~~during this quarter~~ for ~~our food supplements and our own brand of nutraceuticals;~~ ~~SkyPremium Life, which result in higher margins~~.full line wholesale products.

Our future revenue growth will continue to be affected by various factors such as industry growth trends, including drug utilization, the introduction of new innovative brand therapies, the likely increase in the number of generic drugs that will be available over the next few years as a result of the expiration of certain drug patents held by brand-name pharmaceutical manufacturers and the rate of conversion from brand products to those generic drugs, price increases and price deflation, general economic conditions, including the effects of the coronavirus in the member states of European Union, competition within the industry, customer consolidation, changes in pharmaceutical manufacturer pricing and distribution policies and practices, increased downward pressure on government and other third party reimbursement rates to our customers, and changes in government rules and regulations.

~~Gross~~The Company had gross profit of $1,001,335 versus $1,193,171 (a 16.1% decrease) for the three months ended March 31, 2021 and 2020, ~~was $1,193,171 (10%) compared with~~respectively. The decrease in gross profit is due to the ~~$626,162 (6.5%)~~decrease in demand for full line wholesale.

The Company had general and administrative costs of $2,220,268 and $813,870, sales and marketing expenses of $405,092 and $53,729 and depreciation and amortization expense of $107,073 and $100,008 for a net operating loss of $1,731,098 and gain of $225,564 (867% decrease) for the three months ended March 31, ~~2019.~~

~~For~~2021 and 2020 respectively. The increase in expenses is mainly due to the stock-based compensation consulting agreement entered into during the three months ended March 31, 2020, we had general and administrative costs of $867,599 and depreciation and amortization expense of $100,008 for a net operating gain of $225,564. For the three months ended March 31, 2019, we had general and administrative costs of $743,531 and depreciation and amortization expense of $56,373 for a net operating loss of $173,742.

During the three months ended March 31, 2020, other income (expense) was primarily comprised of $412,055 interest expense related to notes payable and convertible notes payable, $29,509 non-cash interest expense related to the amortization of debt discount, a loss on equity investments of $22,172 predominantly related to the Marathon/ICC (f/k/a KBB) transaction, and a foreign currency loss of $227,134. During the three months ended March 31, 2019, other income (expense) was primarily comprised of $259,712 interest expense related to notes payable, $229,713 of non-cash interest expense related to the amortization of debt discount, $606,125 related to the Marathon/ICC (f/k/a KBB) transaction and a foreign currency loss of $160,640.2021.

The Company’s other income (expense) was primarily comprised of interest expense related to notes payable and convertible notes payable $731,826 versus $412,121, non-cash interest expense related to the amortization of debt discount of $50,109 versus $29,509, a gain on equity investments of $440 versus a loss on equity investments $22,172, a gain on extinguishment of debt of $445,636 versus $0 due to an amended debt exchange agreement dated as of February 5, 2021, a change in fair value of derivative liability of $61,373 versus $0 due to agreements on convertible debentures, and a foreign currency loss of $306,020 versus a loss of $227,134 for the three months ended March 31, 2021 and 2020, respectively. Also, The Company’s other income/expense was $178,211 versus $11,434 for the three-months ended March 31, 2021 and 2020, respectively.

~~Additionally, we~~The Company had an unrealized foreign currency loss of $473,578 versus $143,762 and a net comprehensive loss of $2,647,481 versus $627,072 for the three months ended March 31, 2021 and 2020, such that our net comprehensive loss for the period was $627,072 versus the unrealized foreign currency gain of $61,629 for the three months ended March 31, 2019, such that our net comprehensive loss for the period was $155,544.respectively.

At March 31, ~~2020,~~2021, the Company had a working capital ~~deficit~~ of ~~$7,673,520 and a working capital deficit of $7,062,520~~$6,817,608 compared to $5,979,870 as of December 31, ~~2019, respectively.~~2020.

~~At March 31, 2020, the~~The Company had cash of ~~$984,881~~$431,807 versus ~~$38,537~~$628,395 as of March 31, 2021 and December ~~31, 2019. For~~2020, respectively. The Company had net cash used in operating activities of $665,339 and $1,144,755 for the three months ended March 31, 2021 and 2020, ~~net cash used in operating activities was $1,144,739 versus $483,933 net cash used in operating activities for the three months ended Mach 31, 2019.~~respectively. The Company has devoted substantially all of its cash resources to expand through organic business growth and, where appropriate, through the execution of selective company and license acquisitions, and has incurred significant general and administrative expenses in order to enable the financing and growth of its business and operations.

~~During the three months ended March 31, 2020, there was $54,223~~The Company had net cash used in investing activities ~~versus $129,531 net cash used in investing activities~~of $2,310 and $54,223 during the three months ended March 31, ~~2019.~~2021 and 2020, respectively. For the three months ended March 31, ~~2020~~2021 and 2021 this was due to the purchase of fixed assets. ~~For the three months ended March 31, 2020, this was due to proceeds from the sale of investments offset by the purchase of fixed assets.~~

~~During the three months ended March 31, 2020, there was $2,389,703 of~~The Company had net cash provided by financing activities of $380,118 versus ~~$145,808 provided by financing activities~~$2,389,703 during the three months ended March 31, ~~2019.~~ 2021 and 2020, respectively.

For the ~~current~~ quarter ended March 31, ~~2020, the borrowings were as follows: (a) From January 27 to March 23, 2020~~2021, the Company borrowed total net proceeds of ~~$310,000~~$100,000 from an unaffiliated third-party lender. ~~Interest is set~~The convertible note bears interest at ~~5%, paid quarterly in arrears (b) on February 25, 2020, the~~a rate of 8% per annum. The Company ~~borrowed total net~~also received proceeds of ~~$1M~~$250,000 from ~~an unaffiliated~~the sale of treasury shares to a third-party ~~lender with maturity date April 30, 2020. Interest rate I set at 18%, paid quarterly in arrears. In addition,~~and there were proceeds from lines of credit of ~~$4,078,608~~$6,123,067 and payments of lines of ~~credits~~credit of ~~$3,343,162,~~$6,219,899, for a net ~~increase of~~decrease on the line of credit of ~~$735,446.~~$96,832.

We anticipate using cash in our bank account as of March 31, ~~2020,~~2021, cash generated from the operations of the Company and its operating ~~subsidiary~~subsidiaries and from debt or equity financing, or from a loan from management, to the extent that funds are available to do so to conduct our business in the upcoming year. Management is not obligated to provide these or any other funds. If we fail to meet these requirements, we may lose the qualification for quotation and our securities would no longer trade on the ~~over the counter~~over-the-counter markets. Further, as a consequence we would fail to satisfy our reporting obligations with the Securities and Exchange Commission (“SEC”), and investors would then own stock in a company that does not provide the disclosure available in quarterly and annual reports filed with the SEC and investors may have increased difficulty in selling their stock as we will be non-reporting.

As of the date of this report, since March 31, 2020, the Company has borrowed additional net proceeds of $250,000 from the unaffiliated third-party lender who had previously loaned the Company $2,00,000 via five senior promissory notes between April 1 and August 1 of 2019. The senior promissory note matures on October 23, 2020. Interest is set at 15% per annum, paid quarterly in arrears. More information on the senior promissory note is provided in Note 16.

The Company adopted the modified retrospective adoption in accordance with ASC 606 – Revenue from Contracts with Customers, on January 1, 2018. The new guidance introduces a five-step model for recognizing revenue by applying the following steps: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligations are satisfied by transferring the promised goods to the customer. Once these steps are met, revenue is recognized upon delivery of the product. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements.

~~Specifically,~~The pharmaceutical industry is a dynamic industry full of challenges. The fast-changing environment requires our company to have effective strategic planning and monitoring in order to be responsive and adaptable to such challenges.

Our multi-targeted approach is trying to mitigate obstacles by setting out an objective evaluation of the organization’s goals. We set achievable future targets based on past performance, segments and drivers. In addition, we plan and model different scenarios and assess the impact of ~~operations~~later strategic decisions on the business in both short and long term.

We are planning to develop and expand our business ~~through organic growth~~organically by securing new clients, as well as, expanding the amount of business we do with our existing clients. Our resources, industry knowledge, skills, equipment and atlong-term relationships with clients provide us the ~~same level through~~opportunity to focus on the ~~acquisition~~increase of ~~carefully targeted companies that are operating in the pharmaceutical industry and would add value to~~ our ~~Company and its shareholders. Our~~distribution channels. In addition, our organic growth will be driven by ~~entering into new markets and areas where we can sell and distribute a~~distributing more profitable ~~series of~~ pharmaceutical products, OTC medicines, and nutraceuticals. We are committed to capitalizing on sales growth opportunities by expanding our customer pipeline across the European market, as well as entering markets outside the European Union.

We also intend to acquire additional companies that are ~~also committed~~operating in the pharmaceutical industry which would add value to ~~pursuing various forms of business development; this can include trading, alliances, licenses, joint ventures, dispositions~~our Company and ~~acquisitions. Moreover, we hope~~its shareholders giving us the opportunity to ~~continue to build on our portfolio of pharmaceutical products~~penetrate into new markets and ~~expand our product pipeline to generic and nutraceutical products. Thus, we plan to formulate a sound sales distribution network specializing in food supplement~~ products.

Our main objective is expanding the business operations of our subsidiaries by concentrating our efforts on becoming an international manufacturing, trading and distribution pharmaceutical company. We view our business development activity as an enabler of our strategies, and we seek to generate earnings growth and enhance shareholder value by pursuing a disciplined, strategic and financial approach to evaluating business development opportunities. Under these principles we assess our businesses and assets as part of our regular, ongoing portfolio review process and continue to consider trading development activities for our businesses.Nutraceutical Products

The Company inintends to expand and enhance the ~~following~~sales of its own branded nutraceutical products, “Sky Premium Life”, through digital channels across Europe. Also, the plan for the next twelve months ~~intends~~is to ~~substantially grow~~penetrate into the UK market and utilize the current distribution channel of its ~~business operations~~UK subsidiary, Decahedron. The existing portfolio of own braded nutraceutical products reach the number of 67 SGUs as of today and the Company plans to increase it to 150 SGUs within the ~~dietary supplements market and~~next twelve months.

We intend to expand our business within the generic pharmaceutical products ~~market.~~market and obtain more exclusive distribution rights in Europe. These industries are highly competitive and may significantly affect the Company’s sales of these products, including, but not limited to, price and cost-effectiveness, marketing effectiveness, product labeling, quality control and quality assurance. Through our related party, Doc Pharma which is the owner of 47 plus generic licenses of fast-moving product codes we will use innovative products distribution.

In addition, the Company seeks to pursue gross profit margin optimization, by focusing on new revenue streams that would positively affect gross profit, as well as, cost savings. Our objective is to reduce operating expenses across all entities without compromising the quality of our services and products. During the quarter ended March 31, 2020, the expected decline in costs can be seen as operating expenses were reduced by $180,0000 in comparison to the year ended December 31, 2019.

Changes in the behavior and spending patterns of purchasers of pharmaceutical and healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of doctor visits and foregoing healthcare insurance coverage, may impact the Company’s business.

In addition to expanding our product portfolio, we also plan to evaluate offering our products and services to different geographical markets. We are currently focused on our customers throughout the European Union. We plan on expanding our geographical reach to new areas outside of the European Union market, although we currently have no binding agreements, commitments or contracts in any of these geographical markets. Some of the methods we intend to use to accomplish this are: promoting our brand and marketing our products and services through the Internet to new geographic areas, creating strategic relationships with companies in the different geographical regions, and possibly acquiring companies that operate in new geographical regions. We anticipate that we will spend approximately $30,000 evaluating the different methods and regions to which we plan to expand. This cost is made up of primarily legal fees, consulting fees, accounting and auditing fees as well as related development expenses. We assess the foreseeable development of the Company as being positive.B2B/B2C Platforms

We intend to develop platforms for Business-to-Business and Business-to-Customers transactions. We expect our relationships with our customers and suppliers to ~~continue growing~~be redefined, our supply chain management to be improved and our customers loyalty to be increased, as a result, improved sales. We hope the platforms will lead to lower costs and errors avoidance through ~~expansion into adjacent~~the automated process.

The Company intends to enhance its equipment by purchasing one more robotic system which will essentially result in cost savings, time efficiency, errors avoidance and effectiveness. This is expected to lead us to increased productivity, improved safety and make our subsidiary, Cosmofarm S.A., one of the leaders in pharmaceutical products product categories and channels, as well as through entry into new geographic markets. We evaluate potential acquisition targets based on whether they have the capacity to deliver a return on invested capital.distribution.

AsFinally, our goals include to ~~potential acquisitions we are targeting companies that are operating primarily in~~list our Company’s securities on the ~~pharmaceutical sector and~~NEO Stock Exchange within the ~~European Union borders. SEC filing requirements are such that we~~next twelve months which will ~~have~~require higher levels of corporate governance and should provide greater liquidity and greater visibility and access to file audited financial statements of all our operations, including any acquired business. So, we plan that our first step in any potential acquisition process we undertake is to ascertain whether we can obtain audited financials of a company if we were to acquire them. We anticipate that we will spend approximately $50,000 to locate, conduct due diligence, and evaluate possible acquisitions. As noted above, as of the date of this report, we do not have any binding agreements, commitments, or understandings with any potential acquisition candidates.capital.

The pharmaceutical sector offers a large growth potential within the European pharmaceutical market, if service, price and quality are strictly directed towards the customer requirements. We will continue to encounter the competition in the market by product, service, reliability and a high level of quality. On the procurement side we can access a wide range of supply possibilities. To minimize business risks, we diversify our sources of supply all over Europe. We secure our high-quality demands through careful supplier qualification and selection as well as active suppliers’ system management.

We assess the foreseeable development of the Company as being positive. Over the medium term we assume that we will be able to further expand our market shares. However, during the course of further organizational optimization there may be associated extraordinary additional costs.

We still see the risks for the future development in a difficult and competitive environment, increasing purchase prices and the stagnating selling price level. On the background of our financial stability we however see ourselves as being well-equipped for managing the future risks. Risks that could endanger the survival of the Company are currently not able to be identified.

We will evaluate and, where appropriate, execute on opportunities to expand our businesses through the acquisition of products and companies in areas that will serve patients and customers and that we believe will offer above average growth characteristics and attractive margins. In particular, we are looking to continue to enhance our product lines by acquiring or licensing rights to additional products and regularly evaluate selective acquisition and license opportunities. In addition, we remain committed to strategic R&D across each business unit with a particular focus on assets with inherently lower risk profiles and clearly defined governmental regulatory pathways.

As of March ~~31, 2020,~~31,2021, there were no off-balance sheet arrangements.

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” under the Management’s Discussion and Analysis section. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

Revenue Recognition: The Company adopted Topic 606 Revenue from Contracts with Customers on January 1, 2018. As a result, it has changed its accounting policy for revenue recognition as detailed ~~below.~~

Revenue is measured based on consideration specified in a contract with a customer. The Company recognizes revenue when it satisfies a performance obligation by transferring control of a product to a customer. These criteria are assumed to have been met upon delivery of the products requested by the customer to the customers carrier. Hence, adoption of the ASC 606, has not changed the timing and nature of the Company’s revenue recognition.

Foreign Currency. ~~The Company required translation of the Amplerissimo financial statements from euros to dollars since the reverse take-over on September 27, 2013.~~ Assets and liabilities of all foreign operations are translated at year-end rates of exchange, and the statements of operations are translated at the average rates of exchange for the year. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders’ equity until the entity is sold or substantially liquidated. Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity’s local currency) are included in net (loss) earnings.

Income Taxes. The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes, ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

We recognize the impact of an uncertain tax position in our financial statements if, in management’s judgment, the position is not more-likely-then-not sustainable upon audit based on the position’s technical merits. This involves the identification of potential uncertain tax positions, the evaluation of applicable tax laws and an assessment of whether a liability for an uncertain tax position is necessary. We operate and are subject to audit in multiple taxing jurisdictions.

We record interest and penalties related to income taxes as a component of interest and other expense, respectively.

Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted ASC 740 “Accounting for Income Taxes” as of its inception. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in this financial statement because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.

The Company has net operating loss carry-forwards in our parent, Cosmos Holdings Inc., which are applicable to future taxable income in the United States (if any). Additionally, the Company has income tax liabilities in the ~~Republic~~United Kingdom of ~~Cyprus.~~England. The income tax assets and liabilities are not able to be netted. We therefore reserve the income tax assets applicable to the United States, but recognize the income tax liabilities in Greece and the ~~Republic~~United Kingdom of ~~Cyprus.~~

England. Losses may also be subject to limitation under certain rules regarding change of ownership.

Not applicable. A smaller reporting company is not required to provide the information required by this Item.

The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act) that are designed to ensure that information required to be disclosed in the Company’s Securities Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Principal Executive Officer/Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

The Company’s management, with the participation of the Company’s Principal Executive ~~Officer/~~Officer and Principal Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, the Principal Executive Officer and the Principal Financial Officer have concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were ~~not~~partially effective. ~~Management~~The Internal Auditor of the Company has ~~undertaken efforts to remediate~~already developed the material weaknesses identified in the 10-K, which include a lack of segregation of duties, lack of internal controls structure review and documentation of internal policies. Management is in the process of developing such procedures to ensure the effectiveness ofexisting internal controls and ~~procedures for financial~~processes. The Company will also hire one more person to join the internal audit team within 2021 in order to empower the reassurance of regulatory compliance with SEC reporting ~~and is expecting to complete the process in the near future.~~requirements.

During the most recently completed fiscal quarter, there has been a change in our internal control over financial reporting that has materially affected or is reasonably likely to materially affect, our internal control over financial reporting. The Company ~~hired~~has decided to increase its personnel resources in order to eliminate the material weaknesses which have been identified so far. The Company is in the process of hiring an Internal Auditor ~~in October 2019~~Assistant in order to remediate and strengthen existing procedures, as well as to define and develop new policies and ~~controls. The Internal Auditor will also implement SOX (Sarbanes-Oxley)~~ controls in ~~2020 as well as strengthen the understanding of internal procedures for helping to avoid accounting errors and fraudulent practices, as well as~~order to improve the accuracy of the disclosures.

We have appointed new members on board within FY20 in order to advise and help us to ensure the completeness, integrity, reliability and accuracy of our systems, controls and procedures. Our existing Audit Committee is in process of evaluating our existing controls and procedures, whilst communicating with the Management on quarterly basis. We are in process of appointing Nominate and Compensation Committees and preparing the relevant procedures and charters.

We have a separately-designated standing audit committee, which is appointed by the Board of Directors of Cosmos Holdings Inc. Our three independent directors, John Hoidas, Demetrios Demetriades and Peter Goldstein serve on the Audit Committee. Primary function of the committee is to assist the Board of Directors in overseeing (1) the financial reporting and accounting processes of the Company, and (2) the financial statements audits of the Company. The Committee also prepares a written report to be included in the annual proxy statement of the Company pursuant to the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”). In furtherance of these purposes, the Committee shall maintain direct communication among the Company’s independent auditors and the Board of Directors. The independent auditors and any other registered public accounting firm engaged in preparing or issuing an audit report or performing other audit review or attest services for the Company shall report directly to the Committee and are ultimately accountable to the Committee and the Board of Directors.

In discharging its oversight role, the Committee is authorized to investigate any matter brought to its attention with full access to all books, records, facilities and personnel of the Company. The Committee shall have the sole authority to retain at the Company’s expense outside legal, accounting or other advisors to advise the Committee and to receive appropriate funding, as determined by the Committee, from the Company for the payment of the compensation of such advisors and for the payment of ordinary administrative expenses of the Committee that are necessary to carry out its duties. The Committee may request any officer or employee of the Company or the Company’s outside counsel or independent auditors to attend a meeting of the Committee or to meet with any member of, or advisors to, the Committee. The Committee may also meet with the Company’s investment bankers or financial analysts who follow the Company.

The Committee shall meet no less frequently than four times per year, with additional meetings as circumstances warrant. The Committee shall also meet periodically with management, the internal auditors, if any, and the independent auditors in separate executive sessions. The Committee shall record the minutes of all such meetings and shall submit the minutes of its meetings to, or discuss the matters deliberated at each meeting with, the Board of Directors. The Company’s chief financial or accounting officer shall function as the management liaison officer to the Committee.

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Nevada		27-0611758
(State or other jurisdiction of of incorporation or organization)		(I.R.S. Employer Identification No.)

141 West Jackson Blvd, Suite 4236 Chicago, Illinois		60604
(Address of principal executive offices)		(Zip Code)

Large accelerated filer	¨☐	Accelerated filer	¨☐
Non-accelerated filer	¨☐	Smaller reporting company	x☒
(Do not check if a smaller reporting company)		Emerging growth company	¨☐

PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited).

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	3635

Item 3.	Quantitative and Qualitative Disclosures about Market Risk.	4442

Item 4.	Controls and Procedures.	4442

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings.	4544

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	4544

Item 3.	Defaults Upon Senior Securities.	4544

Item 4.	Mine Safety Disclosures.	4544

Item 5.	Other Information.	4544

Item 6.	Exhibits.	4645

SIGNATURES		4746

	Three Months Ended March 31,
	2021			2020

REVENUE	$	11,619,076		$	11,933,248

COST OF GOODS SOLD		10,617,741			10,740,077

GROSS PROFIT		1,001,335			1,193,171

OPERATING EXPENSES
General and administrative expenses		2,220,268			813,870
Sales and marketing expenses		405,092			53,729
Depreciation and amortization expense		107,073			100,008
TOTAL OPERATING EXPENSES		2,732,433			967,607

INCOME (LOSS) FROM OPERATIONS		(1,731,098	)		225,564

OTHER INCOME (EXPENSE)
Other expense, net		(178,211	)		(11,434	)
Interest expense		(731,826	)		(412,121	)
Non-cash interest expense		(50,109	)		(29,509	)
Gain (loss) on equity investments, net		440			(22,172	)
Gain on extinguishment of debt		445,636			-
Change in fair value of derivative liability		61,373			-
Foreign currency transaction loss, net		(306,020	)		(227,134	)
TOTAL OTHER EXPENSE, NET		(758,717	)		(702,370	)

LOSS BEFORE INCOME TAXES		(2,489,815	)		(476,806	)

BENEFIT FROM (PROVISION FOR) INCOME TAXES		315,912			(6,504	)

NET LOSS		(2,173,903	)		(483,310	)

OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustment, net		(473,578	)		(143,762	)

TOTAL COMPREHENSIVE LOSS	$	(2,647,481	)	$	(627,072	)

BASIC NET LOSS PER SHARE	$	(0.14	)	$	(0.04	)
DILUTED NET LOSS PER SHARE	$	(0.14	)	$	(0.04	)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING
Basic		15,034,219			13,225,387
Diluted		15,034,219			13,225,387

COSMOS HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)

	Three Months Ended March 31,
	2020			2019

REVENUE	$	11,933,248		$	9,683,341

COST OF GOODS SOLD		10,740,077			9,057,179

GROSS PROFIT		1,193,171			626,162

OPERATING EXPENSES
General and administrative expenses		867,599			743,531
Depreciation and amortization expense		100,008			56,373
TOTAL OPERATING EXPENSES		967,607			799,904

INCOME (LOSS) FROM OPERATIONS		225,564			(173,742	)

OTHER INCOME (EXPENSE)
Other income (expense), net		(11,434	)		2,357
Interest expense - related party		(66	)		(66	)
Interest expense		(412,055	)		(259,712	)
Non-cash interest expense		(29,509	)		(229,713	)
Gain (loss) on equity investments, net		(22,172	)		606,125
Foreign currency transaction loss, net		(227,134	)		(160,640	)
TOTAL OTHER EXPENSE, NET		(702,370	)		(41,649	)

LOSS BEFORE INCOME TAXES		(476,806	)		(215,391	)

INCOME TAX EXPENSE		(6,504	)		(1,782	)

NET LOSS		(483,310	)		(217,173	)

OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustment, net		(143,762	)		61,629

TOTAL COMPREHENSIVE LOSS	$	(627,072	)	$	(155,544	)

BASIC NET LOSS PER SHARE	$	(0.04	)	$	(0.02	)
DILUTED NET LOSS PER SHARE	$	(0.04	)	$	(0.02	)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING
Basic		13,225,387			13,384,574
Diluted		13,225,387			13,384,574

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

COSMOS HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(Unaudited)

Cosmos Holdings, Inc.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

Cosmos Holdings, Inc.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT


																						Other
	Preferred Stock				Common Stock						Additional		Treasury Stock									Comprehensive			Total
	No. of Shares		Value		No. of Shares			Value			Paid-in Capital		No. of Shares			Value			Accumulated Deficit			Income (Loss)			Stockholders' Deficit

Balance at January 1, 2019		-		-		13,878,757		$	13,879		$	13,133,982		(193,690	)	$	(225,494	)	$	(16,272,645	)	$	32,828		$	(3,317,450	)
Foreign currency translation adjustment, net		-		-		-			-			-		-			-			-			61,629			61,629
Cancellation of pre-delivery shares issued in connection with convertible debentures		-		-		(573,742	)		(574	)		574		-			-			-			-			-
Purchase of treasury stock from third party		-		-		-			-			-		(23,847	)		(71,541	)		-			-			(71,541	)
Net loss		-		-		-			-			-		-			-			(217,173	)		-			(217,173	)
Balance at March 31, 2019		-		-		13,305,015			13,305			13,134,556		(217,537	)		(297,035	)		(16,489,818	)		94,457			(3,544,535	)

Balance at January 1, 2020		-		-		13,225,387		$	13,225		$	13,525,749		(365,328	)	$	(411,854	)	$	(19,571,610	)	$	(16,339	)	$	(6,460,829	)
Foreign currency translation adjustment, net		-		-		-			-			-		-			-			-			(143,762	)		(143,762	)
Net loss		-		-		-			-			-		-			-			(483,310	)		-			(483,310	)
Balance at March 31, 2020		-		-		13,225,387			13,225			13,525,749		(365,328	)		(411,854	)		(20,054,920	)		(160,101	)		(7,087,901	)

The accompanying notes are an integral part of these consolidated financial statements.


																Accumulated
					Additional											Other			Total
	Common Stock				Paid-in		Treasury Stock						Accumulated			Comprehensive			Stockholders’
	No. of Shares		Value		Capital		No. of Shares			Value			Deficit			Income (Loss)			Deficit

Balance at January 1, 2020		13,225,387	$	13,225	$	13,525,749		(365,328	)	$	(411,854	)	$	(19,571,610	)	$	(16,339	)	$	(6,460,829	)
Foreign currency translation adjustment, net		-		-		-		-			-			-			(143,762	)		(143,762	)
Net loss		-		-		-		-			-			(483,310	)		-			(483,310	)
Balance at March 31, 2020		13,225,387	$	13,225	$	13,525,749		(365,328	)	$	(411,854	)	$	(20,054,920	)	$	(160,101	)	$	(7,087,901	)

																Accumulated
					Additional											Other			Total
	Common Stock				Paid-in		Treasury Stock						Accumulated			Comprehensive			Stockholders’
	No. of Shares		Value		Capital		No. of Shares			Value			Deficit			Income (Loss)			Deficit

Balance at January 1, 2021		13,485,128	$	13,484	$	14,333,285		(415,328	)	$	(611,854	)	$	(18,750,824	)	$	854,896		$	(4,161,013	)
Foreign currency translation adjustment, net		-		-		-		-			-			-			(473,578	)		(473,578	)
Sale of treasury stock to third party		-		-		249,350		65,000			650			-			-			250,000
Restriced stock issued to a consultant		1,800,000		1,800		1,187,650														1,189,450
Conversion of notes payable into shares of common stock		781,819		782		2,563,582		-			-			-			-			2,564,364
Net loss		-		-		-		-			-			(2,173,903	)		-			(2,173,903	)
Balance at March 31, 2021		16,066,947	$	16,066	$	18,333,867		(350,328	)	$	(611,204	)	$	(20,924,727	)	$	381,318		$	(2,804,680	)

	Estimated Useful Life
Leasehold improvements and technical works		Lesser of lease term or 40 years
Vehicles		6 years
Machinery		20 years
Furniture, fixtures and equipment		5–10 years
Computers and software		3-5 years

	March 31, 2020						Total Carrying
	Level 1		Level 2		Level 3		Value
Marketable securities – ICC International Cannabis Corp.	$	14,100		-		-	$	14,100
Marketable securities – Divsersa S.A.		196,525		-		-		196,525
Marketable securities – National Bank of Greece		2,275		-		-		2,275
	$	212,900					$	212,900

	March 31, 2021						Total Carrying
	Level 1		Level 2		Level 3		Value
Marketable securities – ICC International Cannabis Corp.	$	-		-		-	$	-
Marketable securities – Divsersa S.A.		209,495		-		-		290,495
Marketable securities – National Bank of Greece		4,854		-		-		4,854
	$	214,349					$	214,349

	December 31, 2019						Total Carrying
	Level 1		Level 2		Level 3		Value
Marketable securities – ICC International Cannabis Corp.	$	33,000		-		-	$	33,000
Marketable securities – Divsersa S.A.		200,290		-		-		200,290
Marketable securities – National Bank of Greece		5,650		-		-		5,650
	$	238,940					$	238,940

	December 31, 2020							Total Carrying
		Level 1		Level 2		Level 3		Value
Marketable securities – ICC International Cannabis Corp.		$	-		-		-	$	-
Marketable securities – Divsersa S.A.			218,183		-		-		218,183
Marketable securities – National Bank of Greece			4,609		-		-		4,609
		$	222,792					$	222,792

	March 31, 2020			December 31, 2019
Leasehold improvements	$	563,304		$	548,000
Vehicles		112,893			115,055
Furniture, fixtures and equipment		1,418,701			1,439,839
Computers and software		106,587			85,052
		2,201,485			2,187,946
Less: Accumulated depreciation and amortization		(496,452	)		(453,165	)
Total	$	1,705,033		$	1,734,781

	March 31, 2020			December 31, 2019
License	$	50,000		$	50,000
Trade name / mark		36,997			36,997
Customer base		176,793			176,793
		263,790			263,790
Less: Accumulated amortization		(58,054	)		(49,806	)
Subtotal		205,736			213,984
Goodwill		49,697			49,697
Total	$	255,433		$	263,681

	a)	The Conversion Price. The Conversion Price shall equal the Variable Conversion Price (subject to stock splits, dividends, rights offerings or similar events) shall mean seventy-five percent (75%) multiplied by the Market Price defined as the average of the three (3) lowest trading prices for common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date.

	b)	Conversion upon Qualified Financing. If the Company engaged in a registered offering resulting in an “uplisting” to a higher-tiered trading market (a “Qualified Financing”), the Holder has the option to convert any outstanding debt due under this Note at seventy-five (75%) of the per share offering price.

	c)	Conversion Price During Major Announcements. In the event the Borrower (i) makes a public announcement that it intends to consolidate or merge with any other Company (other than a merger in which the Borrower is the surviving or continuing Company and its capital stock is unchanged or sell or transfer all or substantially all of the assets of the Borrower or (ii) any person, group or entity (including the Borrower) publicly announces a tender offer to purchase fifty percent (50%) or more of the Borrower’s Common Stock (or any other takeover scheme), then the Conversion Price shall, effective upon the announcement date shall be equal to the lower of (x) the Conversion Price which would have been applicable for a Conversion occurring on the Announcement Date and (y) the Conversion Price that would otherwise be in effect.


	Amount
Balance on December 31, 2020	$	460,728
Issuances to debt discount		62,619
Change in fair value of derivative liabilities		(61,373	)
Balance on March 31, 2021	$	461,974

	March 31, 2021
Dividend yield		0	%
Expected volatility		121.3%-137.6	%
Risk free interest rate		0.13%-0.17	%
Contractual terms (in years)		0.59 – 0.81

March 31, 2020	Loan Facility		Bridge Loans		Trade Facility			Third Party			Total
Beginning balance	$	3,078,442	$	191,287	$	6,245,400		$	2,514,595		$	12,029,724
Proceeds		-		-		-			1,310,000			1,310,000
Payments		-		-		-			(227,912	)		(227,912	)
Foreign currency translation		-		-		(42,200	)		(62	)		(42,262	)
Ending Balance	$	3,078,442	$	191,287	$	6,203,200		$	3,824,533		$	13,297,462

March 31, 2021	Loan Facility			Trade Facility			Third Party			COVID Loans			Total
Beginning balance		3,302,100			6,446,000			12,631,284			435,510			22,814,594
Proceeds		-			-			-			-			-
Payments		-			-			-			-			-
Conversion of debt		-			-			(3,010,000	)		-			(3,010,000	)
Foreign currency translation		(131,490	)		(97,400	)		(24,740	)		(13,945	)		(267,575	)
Reclass of long-term portion of debt														(10,303,924	)
Ending Balance		3,171,610			6,348,600			9,596,544			421,265			9,233,095

	·	~~The Lender will provide Decahedron a facility of up to €2,750,000 ($3,424,850) secured against Decahedron’s receivables from the sale of branded and generic pharmaceutical sales.~~

	·	~~The total facility will be calculated as 95% of the agreed upon value of Decahedron’s receivables.~~

·	~~The term of the Decahedron Facility will be for 12 months.~~

·	~~The obligations of Decahedron are guaranteed by the Company pursuant to a Cross Guarantee and Indemnity Agreement.~~

·	~~The Lender has the right to make payments directly to Decahedron’s suppliers.~~

·	~~The following fees should be paid in connection with the Decahedron Facility:~~

	o	~~2% of the maximum principal amount as an origination fee.~~

	o	~~A one percent (1%) monthly fee.~~

·•	The Lender will provide SkyPharm a facility of up to €2,000,000 ($~~2,203,200)~~2,348,600) secured against SkyPharm’s receivables from the sale of branded and generic pharmaceutical sales. In the event that accounts receivable become uncollectible, the Company will be obligated to pay back the notes in full.

·•	The total facility will be calculated as 95% of the agreed upon value of Decahedron’s receivables.

·•	The term of the SkyPharm Facility will be for 12 months.

·•	The obligations of SkyPharm are guaranteed by the Company pursuant to a Cross Guarantee and Indemnity Agreement.

·•	The Lender has the right to make payments directly to SkyPharm’s suppliers.

·•	The following fees should be paid in connection with the SkyPharm Facility:

	o	2% of the maximum principal amount as an origination fee.

	o	A one percent (1%) monthly fee.

	·•	A listing of approved purchasers;

	·•	To permit SkyPharm to request Synthesis to make payments under the TFF directly to SkyPharm so that SkyPharm can discharge its obligations to a commodity seller directly;

	·•	To prohibit SkyPharm from entering into a commodity contract which grants more than seventy-five (75) days delay between the payment for products and receipt of the purchase price and placed other limitations on terms of commodity contracts;

	·•	If Grigorios Siokas, CEO of Cosmos Holdings Inc. (“Cosmos”), ceases to own or control at least fifty-one (51%) percent of the shares of Cosmos, or SkyPharm ceases to be a wholly-owned subsidiary of Cosmos, either event shall constitute an Event of Default (as defined);

	·•	The maximum aggregate amount of the TFF is €15,000,000, although there is no commitment for any future loans under the TFF;

	·•	The interest rate on the TFF for: (i) all lending in U.S. dollars is the one-month LIBOR plus six (6%) percent margin; and (ii) for all lending in Euro, the one-month Euribor Rate plus six (6%) percent per annum, commencing June 1, 2018.

	·•	Synthesis is permitted to terminate the TFF at any time and demand repayment of all outstanding principal and interest in full within six (6) months from the date of notification.

Maturity of Lease Liability
Remainder of 2020	$	114,222
2021		80,728
2022		52,877
2023		52,877
2024		52,877
Thereafter		198,288
Total undiscounted finance lease payments	$	551,869
Less: Imputed interest		111,722
Present value of finance lease liabilities	$	440,146

Maturity of Lease Liability
Remainder of 2021	$	202,886
2022		226,636
2023		202,152
2024		60,485
2025		56,366
Thereafter		154,975
Total undiscounted operating lease payments	$	903,500
Less: Imputed interest		(133,728	)
Present value of operating lease liabilities	$	769,772

Maturity of Lease Liability
Remainder of 2020	$	44,001
2021		45,391
2022		27,831
2023		16,268
2024		4,047
Thereafter		-
Total undiscounted finance lease payments	$	137,539
Less: Imputed interest		12,828
Present value of finance lease liabilities	$	124,710

Maturity of Lease Liability
Remainder of 2021	$	73,974
2022		76,682
2023		66,780
2024		51,176
2025		20,716
Thereafter		584
Total undiscounted finance lease payments	$	289,912
Less: Imputed interest		(33,014	)
Present value of finance lease liabilities	$	256,898

	·	~~50,000 shares upon the successful conclusion of Preclinical Trials.~~

	·	~~50,000 shares upon the conclusion of Phase I testing.~~

	·	~~50,000 shares upon the conclusion of Phase II testing.~~

	·	~~50,000 shares upon the conclusion of Phase III testing.~~

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Number of		Exercise		Contractual		Intrinsic
Options	Shares		Price		Term		Value
Balance Outstanding, December 31, 2019		74,000	$	1.32		2.47	$	198,000
Granted		-		-		-		-
Forfeited		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Balance Outstanding, March 31, 2020		74,000	$	1.32		1.32	$	24,750

Exercisable, March 31, 2020		74,000	$	1.32		1.32	$	24,750

	·	Drug shortages due to ban of exports

	·	Problems/restrictions in supply chain

	·	Logistics delays ~~(5-7 days)~~

	·	National or EU long lasting recession ·Restrictions on employees’ ability to work ~~(10% of employees are working from home)~~

	·	Liquidity issues (AR/AP) – payment delays and new government regulations for freezing payment terms Subsequent to year-end, management has identified opportunities as listed below, that could balance, at least in part, the adverse effects of COVID-19 during the fiscal year-end 2020. However, there can be no assurance that this will occur prior to a vaccine and treatment becoming effective. Opportunities · Sales increase of OTC products branded · Sales increase of food supplements (Vitamin D3, Vitamin C, multivitamins) · Sales increase of antibacterial products and medicine masks · Obtain exclusive distribution rights for detection test kits for COVID-19 · Governmental financing incentives related to liquidity · VAT incentives (in the UK the VAT of imports is waived on medical products)


37

	·	~~National or EU long lasting recession~~Table of Contents

Exhibit No.		Document Description

10.1		~~Form of~~Debt Exchange Agreement dated May ~~5, 2020 Senior Promissory Note with Personal Guaranty of~~10. 2021 by and between Cosmos Holdings, Inc. and Grigorios ~~Siokas~~Siokas.

~~10.2~~31.1*		~~Form~~Certification of ~~May 8, 2020 Senior Promissory Note with Personal Guaranty~~CEO pursuant to Section 302 of ~~Grigorios Siokas~~the Sarbanes-Oxley Act of 2002.

~~31.1~~31.2*		Certification of ~~CEO/~~CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of ~~CEO/~~CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*		Certification of CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

101.INS		XBRL Instance Document**

101.SCH		XBRL Taxonomy Extension Schema Document**

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document**

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document**

101.LAB		XBRL Taxonomy Extension Label Linkbase Document**

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document**

*	This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

**	XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.